Office of Directorate General of Foreign Trade
New Delhi -0

Para 4.7 Decision

Minutes of the Norms Committee – 3 Meeting No. 6/82-ALC4/2019 dated 16.08.2019 (actually held on 23.08.2019) for considering the cases/issues under Duty Exemption Scheme (Chapter-4) of Foreign Trade Policy, 2015-20 pertaining to Chemical and Allied products falling under Chapter 29 and 30, held under the Chairmanship of Shri Satyan Sharda, Addl. DGFT in Room No.11, Udyog Bhawan, New Delhi.

Following members were present:-

(i) Shri Nirmal Kumar, Dy. Director General of Foreign Trade
(ii) Shri Ajay Kumar, Assistant Director
(iii) Consultant, Technical Expert Pharmaceuticals
(iv) Consultant, Technical Expert Chemicals

The committee went through the minutes of earlier meeting No. 4/82-ALC4/2019 dated 19.07.2019 and 5/82-ALC4/2019 dated 12.08.2019 and approved the same.

MEETING NUMBER : 6/82-ALC4/2019 **MEETING DATE** : 16.08.2019
(actually held on 23.08.2019)

1	**Case No.:141/6/82-ALC4/2019**	Party Name:COVALENT LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00367/AM20/	RLA File :09/24/040/00108/AM10/	Lic.No/Date:0910038898 12.08.2009	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 5/82-ALC4/2019 , dated 02.08.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
CEFPODOXIME PROXETIL	1 kg	1	7 Amino Cephalosporonic Acid (7 ACA)	0.8378 kg
		2	2- Mercapto- Benzothiazol- 2- Aminothiazole- 4yl- Methoxyimino Acetate (MAEM)	0.8378 kg
		3	Alpha-Chloroethyl Isopropyl Carbonate (CEIPC)	0.550 kg
		4	1,1,3,3, - tetramethyl Guanidine (TMG)	0.223 kg
		5	Methanol	1.51 kg
		6	Methylene Chloride	2.32 kg
		7	Acetone	2.50 kg
		8	Tetra Hydro Furan	1.56 kg
		9	Sodium Iodide	0.28 kg
		10	Activated Carbon	0.100 kg

RA concerned may take further necessary action as per above decision of NC.

2	**Case No.:225/6/82-ALC4/2019**	Party Name:KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00451/AM20/	RLA File :07/24/040/00480/AM12/	Lic.No/Date:0710086623 28.02.2012	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
AMIKACIN SULPHATE INJECTION USP 500MG/2ML EACH VIAL CONTAINS:AMIKACIN 500MG EQUIVALENT TO AMIKACIN SULPHATE USP	1 Number	1	AMIKACIN SULPHATE USP	715.81 mg / 2 ml vial

RA concerned may take further necessary action as per above decision of NC.

3	**Case No.:140/6/82-ALC4/2019**	Party Name:INCHEM LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00366/AM20/	RLA File :09/70/040/00077/AM14/	Lic.No/Date:0910057229 19.08.2013	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Sodium Valproate	1 kg	1	N-Propyl Bromide	2.91 kg
		2	Diethyl Malonate	1.45 kg

RA concerned may take further necessary action as per above decision of NC.

4	**Case No.:226/6/82-ALC4/2019**	Party Name:MYLAN LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00452/AM20/	RLA File :09/24/040/00615/AM14/	Lic.No/Date:0910059463 28.02.2014	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
OLMESARTAN MEDOXOMIL	1 kg	1	Ethyl Ester of 4-(Hydroxy-1-Methylethyl)-2-Propylimidazole-5-Carboxylic Acid (Imidazole Ester) (or) 1H-Imidazole-4-Carboxylic Acid, 5-(1-Hydroxy-1-Methylethyl)-2-Propyl Ethyl Ester	0.70 kg
		2	Potassium carbonate	0.50 kg
		3	Acetonitrile	2.00 kg
		4	Isopropyl alcohol	4.20 kg
		5	4-chloro methyl-5-methyl-2-oxo-1,3-dioxolene (or) 4-chloromethyl-5-methyl-1,3-dioxolen-2-one	0.426 kg
		6	Methanol	2.60 kg
		7	CECA carbon (Activated Carbon (ENOPC))	0.100 kg
		8	Toluene	2.40 kg

RA may take appropriate action as per the decision of Norms Committee

5	**Case No.:269/6/82-ALC4/2019**	Party Name:BIOCON LIMITED,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00495/AM20/	RLA File :07/24/040/00482/AM14/	Lic.No/Date:0710103216 26.03.2014	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
ACARBOSE PH.EUR BULK DRUG	1200 kg	1	ACARBOSE BULK DRUG	1200 kg

RA concerned may take further necessary action as per above decision of NC.

6	**Case No.:139/6/82-ALC4/2019**	Party Name:PCL OIL & SOLVENTS LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00365/AM20/	RLA File :05/24/040/00030/AM15/	Lic.No/Date:0510393090 05.02.2015	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 3/82-ALC4/2019 , dated 05.07.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
PVC Plasticizer(DOP)	1 kg	1	PHTHALIC ANHYDRIDE	0.400 kg
		2	2 ETHYLHEXANOL (OCTANOL)	0.700 kg

RA concerned may take further necessary action as per above decision of NC.

7	**Case No.:196/6/82-ALC4/2019**	Party Name:PCL OIL & SOLVENTS LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00422/AM20/	RLA File :05/24/040/00585/AM15/	Lic.No/Date:0510393538 12.03.2015	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 3/82-ALC4/2019 , dated 05.07.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
PVC Plasticizer(DOP)	1 kg	1	PHTHALIC ANHYDRIDE	0.400 kg
		2	2 ETHYLHEXANOL (OCTANOL)	0.700 kg

RA concerned may take further necessary action as per above decision of NC.

8	**Case No.:197/6/82-ALC4/2019**	Party Name:PCL OIL & SOLVENTS LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00423/AM20/	RLA File :05/24/040/00482/AM15/	Lic.No/Date:0510393589 16.03.2015	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 3/82-ALC4/2019 , dated 05.07.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
PVC Plasticizer(DOP)	1 kg	1	PHTHALIC ANHYDRIDE	0.400 kg
		2	2 ETHYLHEXANOL (OCTANOL)	0.700 kg

RA concerned may take further necessary action as per above decision of NC.

9	**Case No.:173/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00399/AM20/	RLA File :03/94/040/00301/AM16/	Lic.No/Date:0310797781 29.07.2015	Defer Date:
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was observed that the import quantity worked out by the firm in the subject Advance Authorization does not match with the export obligation shown in the application. Such details are confusing in all the export items. The firm may be, at first instance, advice to get the license amended from RA.			

10	**Case No.:174/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00400/AM20/	RLA File :03/94/040/00241/AM17/	Lic.No/Date:0310805840 30.06.2016	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg(Pack Size 90 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 No. of Capsule	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	Relevant, as per packing policy
2	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	Relevant, as per packing policy

3	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg (Pack Size 500 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	
			7	950CC WHITE HDPE BOTTLE WITH 53MM NECK DB-22 TRIVENI PLASTIC (500 Count) 750mg	Relevant net to net
			8	53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH 53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH (500 Count) 750mg	
4	Potassium Chloride Extended Release Capsules 600mg / Potassium Chlor ER Caps USP 600mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 600mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	612.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	8.0 mg
			3	DIBUTYL SEBACATE NF	9.6 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	

RA may take appropriate action as per the decision of Norms Committee.

11	**Case No.:175/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00401/AM20/	RLA File :03/94/040/00242/AM17/	Lic.No/Date:0310805842 30.06.2016	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Quantity allowed in mg/tablet
Telmisartan and Amlodipine Tablets 40/10mg Each uncoated tablets contains : Telmisartan 40 mg Telmisartan 40 mg equivalent to Telmisartan granules 67.36mg/ Amlodipine Besilate equivalent to Amlodipine USP 10mg	1 Number	1	Telmisartan Granules	68.034
		2	Amlodipine Besilate	10.20
Telmisartan and Amlodipine Tablets 80/10mg Each uncoated tablets contains : Telmisartan 80 mg Telmisartan 80 mg equivalent to Telmisartan granules 134.72mg Amlodipine Besilate equivalent to Amlodipine USP 10mg	1 Number	1	Telmisartan Granules	136.067
		2	Amlodipine Besilate	10.20
Telmisartan and Amlodipine Tablets 40/5mg Each uncoated tablets contains : Telmisartan 40 mg Telmisartan 40 mg equivalent to Telmisartan granules 67.36mg Amlodipine Besilate equivalent to Amlodipine USP 5mg	1 Number	1	Telmisartan Granules	68.034
		2	Amlodipine Besilate	5.10
Telmisartan and Amlodipine Tablets 80/5mg Each uncoated tablets contains : Telmisartan 80 mg Telmisartan 80 mg equivalent to Telmisartan granules 134.72mg Amlodipine Besilate equivalent to Amlodipine USP 5mg	1 Number	1	Telmisartan Granules	136.067
		2	Amlodipine Besilate	5.10

RA may take appropriate action as per the decision of Norms Committee.

12	**Case No.:176/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00402/AM20/	RLA File :03/94/040/00247/AM17/	Lic.No/Date:0310805843 30.06.2016	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Quantity allowed in mg/tablet
Telmisartan and Amlodipine Tablets 40/10mg Each uncoated tablets contains : Telmisartan 40 mg Telmisartan 40 mg equivalent to Telmisartan granules 67.36mg/ Amlodipine Besilate equivalent to Amlodipine USP 10mg	1 Number	1	Telmisartan Granules	68.034
		2	Amlodipine Besilate	10.20
Telmisartan and Amlodipine Tablets 80/10mg Each uncoated tablets contains : Telmisartan 80 mg Telmisartan 80 mg equivalent to Telmisartan granules 134.72mg Amlodipine Besilate equivalent to Amlodipine USP 10mg	1 Number	1	Telmisartan Granules	136.067
		2	Amlodipine Besilate	10.20
Telmisartan and Amlodipine Tablets 40/5mg Each uncoated tablets contains : Telmisartan 40 mg Telmisartan 40 mg equivalent to Telmisartan granules 67.36mg Amlodipine Besilate equivalent to Amlodipine USP 5mg	1 Number	1	Telmisartan Granules	68.034
		2	Amlodipine Besilate	5.10
Telmisartan and Amlodipine Tablets 80/5mg Each uncoated tablets contains : Telmisartan 80 mg Telmisartan 80 mg equivalent to Telmisartan granules 134.72mg Amlodipine Besilate equivalent to Amlodipine USP 5mg	1 Number	1	Telmisartan Granules	136.067
		2	Amlodipine Besilate	5.10

RA may take appropriate action as per the decision of Norms Committee.

13	**Case No.:177/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00403/AM20/	RLA File :03/94/040/00254/AM17/	Lic.No/Date:0310805844 30.06.2016	Defer Date:
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information: (i) Copy of Master Batch Formula duly authenticated by Quality Control Incharge for each export item showing the net weight of each input in the export items.			

14	**Case No.:178/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00404/AM20/	RLA File :03/94/040/00266/AM17/	Lic.No/Date:0310805888 01.07.2016	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Budesonide Inhalation Suspension 0.25mg/2ml Budesonide Respules 0.25mg/2ml (Each 2ml contains Budesonide USP 0.25mg)	1 Number	1	Budesonide USP	0.2625 mg / 0.25 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)
Budesonide Inhalation Suspension 0.50mg/2ml Budesonide Respules 0.50mg/2ml (Each 2ml contains Budesonide USP 0.50mg)	1 Number	1	Budesonide USP	0.525 mg / 0.50 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)
Budesonide Inhalation Suspension 1mg/2ml Budesonide Respules 1mg/2ml (Each 2ml contains Budesonide USP 1mg)	1 Number	1	Budesonide USP	1.05 mg / 1 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)

RA concerned may take further necessary action as per above decision of NC.

15	**Case No.:179/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00405/AM20/	RLA File :03/94/040/00257/AM17/	Lic.No/Date:0310805901 04.07.2016	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

16	**Case No.:180/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00406/AM20/	RLA File :03/94/040/00756/AM17/	Lic.No/Date:0310809333 25.11.2016	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Quantity allowed
Budesonide Inhalation Suspension 0.25mg/2ml Budesonide Respules 0.25mg/2ml (Each 2ml contains Budesonide USP 0.25mg)	1 Number	1	Budesonide USP	0.2625 mg / 0.25 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)
Budesonide Inhalation Suspension 0.50mg/2ml Budesonide Respules 0.50mg/2ml (Each 2ml contains Budesonide USP 0.50mg)	1 Number	1	Budesonide USP	0.525 mg / 0.50 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)
Budesonide Inhalation Suspension 1mg/2ml Budesonide Respules 1mg/2ml (Each 2ml contains Budesonide USP 1mg)	1 Number	1	Budesonide USP	1.05 mg / 1 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)

RA concerned may take further necessary action as per above decision of NC.

17	**Case No.:181/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00407/AM20/	RLA File :03/94/040/01100/AM17/	Lic.No/Date:0310811828 15.03.2017	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg(Pack Size 90 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 No. of Capsule	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	Relevant, as per packing policy
2	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	Relevant, as per packing policy
3	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP	1 no. of capsules	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml

	750mg (Pack Size 500 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg		5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	
			7	950CC WHITE HDPE BOTTLE WITH 53MM NECK DB-22 TRIVENI PLASTIC (500 Count) 750mg	Relevant net to net
			8	53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH 53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH (500 Count) 750mg	
4	Potassium Chloride Extended Release Capsules 600mg / Potassium Chlor ER Caps USP 600mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 600mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	612.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	8.0 mg
			3	DIBUTYL SEBACATE NF	9.6 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	

RA may take appropriate action as per the decision of Norms Committee.

18	**Case No.:182/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00408/AM20/	RLA File :03/94/040/00016/AM18/	Lic.No/Date:0310812686 24.04.2017	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Quantity allowed
Budesonide Inhalation Suspension 0.25mg/2ml Budesonide Respules 0.25mg/2ml (Each 2ml contains Budesonide USP 0.25mg)	1 Number	1	Budesonide USP	0.2625 mg / 0.25 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)
Budesonide Inhalation Suspension 0.50mg/2ml Budesonide Respules 0.50mg/2ml (Each 2ml contains Budesonide USP 0.50mg)	1 Number	1	Budesonide USP	0.525 mg / 0.50 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)
Budesonide Inhalation Suspension 1mg/2ml Budesonide Respules 1mg/2ml (Each 2ml contains Budesonide USP 1mg)	1 Number	1	Budesonide USP	1.05 mg / 1 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)

RA concerned may take further necessary action as per above decision of NC.

19	**Case No.:183/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00409/AM20/	RLA File :03/94/040/00057/AM18/	Lic.No/Date:0310813088 05.05.2017	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 4/82-ALC4/2019
, dated 16.07.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.
Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray / Dymista Nasal Spray (Pack 120MD) Each Spray delivers: Azelastine Hydrochloride BP 137mcg Fluticasone Propionate 50mcg	1 Number

Sl. No.	Import items	Qty.
1	Azelastine Hydrochloride	16.44 mg
2	Fluticasone Propionate	6.00 mg
3	140MCL PUMPS	Net + 1 %
4	25ML USP TYPE I AMBER GLASS VIAL.	
5	NASAL ACTUATOR	

RA concerned may take further necessary action as per above decision of NC.

20	**Case No.:184/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00410/AM20/	RLA File :03/94/040/00118/AM18/	Lic.No/Date:0310813385 18.05.2017	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Quantity allowed in mg/tablet
Telmisartan and Amlodipine Tablets 40/10mg Each uncoated tablets contains : Telmisartan 40 mg Telmisartan 40 mg equivalent to Telmisartan granules 67.36mg/ Amlodipine Besilate equivalent to Amlodipine USP 10mg	1 Number	1	Telmisartan Granules	68.034
		2	Amlodipine Besilate	10.20
Telmisartan and Amlodipine Tablets 80/10mg Each uncoated tablets contains : Telmisartan 80 mg Telmisartan 80 mg equivalent to Telmisartan granules 134.72mg Amlodipine Besilate equivalent to Amlodipine USP 10mg	1 Number	1	Telmisartan Granules	136.067
		2	Amlodipine Besilate	10.20

Telmisartan and Amlodipine Tablets 40/5mg Each uncoated tablets contains : Telmisartan 40 mg Telmisartan 40 mg equivalent to Telmisartan granules 67.36mg Amlodipine Besilate equivalent to Amlodipine USP 5mg	1 Number	1	Telmisartan Granules	68.034
		2	Amlodipine Besilate	5.10
Telmisartan and Amlodipine Tablets 80/5mg Each uncoated tablets contains : Telmisartan 80 mg Telmisartan 80 mg equivalent to Telmisartan granules 134.72mg Amlodipine Besilate equivalent to Amlodipine USP 5mg	1 Number	1	Telmisartan Granules	136.067
		2	Amlodipine Besilate	5.10

RA may take appropriate action as per the decision of Norms Committee.

21

Case No.:137/6/82-ALC4/2019	Party Name:S M S PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
HQ File :01/82/050/00363/AM20/	RLA File :09/24/040/00097/AM18/	Lic.No/Date:0910065087 23.05.2017	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
EFAVIRENZ	1 kg	1	(S)-5-Chloro-Alpha-(Cyclo Propyl Ethynyl)-2-Amino-Alpha-(Tri Fluoro Methyl) Benzene Methanol	0.987 kg
		2	TRIPHOSGENE	0.431 kg

RA concerned may take further necessary action as per above decision of NC.

22	**Case No.:185/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00411/AM20/	RLA File :03/94/040/00161/AM18/	Lic.No/Date:0310813599 26.05.2017	

Decision: The Committee considered case as per agenda and deliberated on the matter in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

A. For 1 Number of Export Item

Sl. No.	Export Product	Qty. in mg	
		Abacavir Sulfate	Lamivudine
1	Abacavir Sulfate and Lamivudine Dispersible Tablets 60/30mg Abacavir Sulfate and Lamivudine Tablets for Oral Suspension 60/30mg Abamune - L Baby Tablets	61.20	30.60
2	Abacavir and Lamivudine Tablets 600/300 mg Abacavir Sulfate 600mg and Lamivudine 300mg Tablet	612.0	306.0

B. Norms for 1 kg Abacavir Sulfate

Sl. No.	Import Item	Qty.
1	Formamido Amino Dichloro Pyrimidine (FADCP)	1.042 kg
2	Methylene Chloride	3.00 kg
3	Cyclopropyl Amine	0.19 kg

C. Norms for 1 kg Lamivudine

Sl. No.	Import Item	Qty.
1	(1 R, 2 S, 5 R)- MENTHYL-5S-(CYTOSINE-1 -YL)-1,3-OXATHIOLANE- 2R-CARBOXYLATE / CME COMPOUND"	2.19 kg
2	SODIUM BOROHYDRIDE	0.48 kg

RA concerned may take further necessary action as per above decision of NC.

23	**Case No.:186/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00412/AM20/	RLA File :03/94/040/00190/AM18/	Lic.No/Date:0310813761 05.06.2017	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg(Pack Size 90 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 No. of Capsule	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	Relevant, as per packing policy
2	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	Relevant, as per packing policy
3	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg (Pack Size 500 Capsules Each) Each extended Release Capsule	1 no. of capsules	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING	

	contains: Potassium Chloride USP 750mg			UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	
			7	950CC WHITE HDPE BOTTLE WITH 53MM NECK DB-22 TRIVENI PLASTIC (500 Count) 750mg	Relevant net to net
			8	53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH 53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH (500 Count) 750mg	
4	Potassium Chloride Extended Release Capsules 600mg / Potassium Chlor ER Caps USP 600mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 600mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	612.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	8.0 mg
			3	DIBUTYL SEBACATE NF	9.6 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	

RA may take appropriate action as per the decision of Norms Committee.

24

Case No.:192/6/82-ALC4/2019	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
HQ File :01/82/050/00418/AM20/	RLA File :03/94/040/00235/AM18/	Lic.No/Date:0310814259 27.06.2017	

Decision: The Committee considered case as per agenda and deliberated on the matter in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

A. For 1 Number of Export Item

Sl. No.	Export Product	Qty. in mg	
		Abacavir Sulfate	Lamivudine
1	Abacavir and Lamivudine Tablets 600/300 mg Abacavir Sulfate 600mg and Lamivudine 300mg Tablet	612.0	306.0

B. Norms for 1 kg Abacavir Sulfate

Sl. No.	Import Item	Qty.
1	Formamido Amino Dichloro Pyrimidine (FADCP)	1.042 kg
2	Methylene Chloride	3.00 kg
3	Cyclopropyl Amine	0.19 kg

C. Norms for 1 kg Lamivudine

Sl. No.	Import Item	Qty.
1	(1 R, 2 S, 5 R)- MENTHYL-5S-(CYTOSINE-1 -YL)-1,3-OXATHIOLANE- 2R-CARBOXYLATE / CME COMPOUND"	2.19 kg
2	SODIUM BOROHYDRIDE	0.48 kg

RA concerned may take further necessary action as per above decision of NC.

25

Case No.:187/6/82-ALC4/2019	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
HQ File :01/82/050/00413/AM20/	RLA File :03/94/040/00372/AM18/	Lic.No/Date:0310814909 31.07.2017	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg(Pack Size 90 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 No. of Capsule	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	Relevant, as per packing policy
2	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	Relevant, as per packing policy

3	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg (Pack Size 500 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	
			7	950CC WHITE HDPE BOTTLE WITH 53MM NECK DB-22 TRIVENI PLASTIC (500 Count) 750mg	Relevant net to net
			8	53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH 53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH (500 Count) 750mg	
4	Potassium Chloride Extended Release Capsules 600mg / Potassium Chlor ER Caps USP 600mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 600mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	612.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	8.0 mg
			3	DIBUTYL SEBACATE NF	9.6 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	

RA may take appropriate action as per the decision of Norms Committee.

26	**Case No.:188/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00414/AM20/	RLA File :03/94/040/00553/AM18/	Lic.No/Date:0310816515 25.10.2017	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 4/82-ALC4/2019
, dated 16.07.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.
Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray / Dymista Nasal Spray (Pack 120MD) Each Spray delivers: Azelastine Hydrochloride BP 137mcg Fluticasone Propionate 50mcg	1 Number

Sl. No.	Import items	Qty.
1	Azelastine Hydrochloride	16.44 mg
2	Fluticasone Propionate	6.00 mg
3	140MCL PUMPS	Net + 1 %
4	25ML USP TYPE I AMBER GLASS VIAL.	
5	NASAL ACTUATOR .	

RA concerned may take further necessary action as per above decision of NC.

27	**Case No.:190/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00416/AM20/	RLA File :03/94/040/00652/AM18/	Lic.No/Date:0310817507 05.12.2017	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg(Pack Size 90 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 No. of Capsule	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	Relevant, as per packing policy

2	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	Relevant, as per packing policy
3	Potassium Chloride Extended Release Capsules 750mg / Potassium Chlor ER Caps USP 750mg (Pack Size 500 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 750mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	765.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	10.0 mg
			3	DIBUTYL SEBACATE NF	12.0 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	
			7	950CC WHITE HDPE BOTTLE WITH 53MM NECK DB-22 TRIVENI PLASTIC (500 Count) 750mg	Relevant net to net
			8	53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH 53/400 LSC, SCREW CAP HAVING UNIPAC SG-75M LINER PTD. WITH (500 Count) 750mg	
4	Potassium Chloride Extended Release Capsules 600mg / Potassium Chlor ER Caps USP 600mg (Pack Size 100 Capsules Each) Each extended Release Capsule contains: Potassium Chloride USP 600mg	1 no. of capsules	1	POTASSIUM CHLORIDE USP	612.0 mg
			2	CITRIC ACID (MONOHYDRATE USP)	8.0 mg
			3	DIBUTYL SEBACATE NF	9.6 mg
			4	ETHANOL USP 99.9%	2.62 ml
			5	200CC WHITE HDPE BOTTLE WITH 38MM NECK DB-02 TRIVENI PLASTIC (100 Count) 750mg / (100 count 600 mg)	Relevant, as per packing policy
			6	38/400 FG, CRC HAVING UNIPAC SG-75M LINER PTD. WITH SFYP IN BLACK (REXAM CLOSURES) (90 Count) (100 Count) 750mg / (100 count) 600mg	

RA may take appropriate action as per the decision of Norms Committee.

28	**Case No.:227/6/82-ALC4/2019**	Party Name:AMI ORGANICS PVT LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00453/AM20/	RLA File :52/24/040/00047/AM18/	Lic.No/Date:5210042448 05.12.2017	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	S. No.	Import Product	Qty.
3,4 DI HYDROXY 5 NITRO BENZAL DEHYDE-99% min	1 kg	1	VANILLINE- 99.5 % min	1.588 kg
		2	DI METHYL FORMAMIDE - 99.5%	3.17 kg

RA may take appropriate action as per the decision of Norms Committee.

29	**Case No.:189/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00415/AM20/	RLA File :03/94/040/00614/AM18/	Lic.No/Date:0310818040 27.12.2017	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Quantity allowed in mg/tablet
Telmisartan and Amlodipine Tablets 40/10mg Each uncoated tablets contains : Telmisartan 40 mg Telmisartan 40 mg equivalent to Telmisartan granules 67.36mg/ Amlodipine Besilate equivalent to Amlodipine USP 10mg	1 Number	1	Telmisartan Granules	68.034
		2	Amlodipine Besilate	10.20
Telmisartan and Amlodipine Tablets 80/10mg Each uncoated tablets contains : Telmisartan 80 mg Telmisartan 80 mg equivalent to Telmisartan granules 134.72mg Amlodipine Besilate equivalent to Amlodipine USP 10mg	1 Number	1	Telmisartan Granules	136.067
		2	Amlodipine Besilate	10.20
Telmisartan and Amlodipine Tablets 40/5mg Each uncoated tablets contains : Telmisartan 40 mg Telmisartan 40 mg equivalent to Telmisartan granules 67.36mg Amlodipine Besilate equivalent to Amlodipine USP 5mg	1 Number	1	Telmisartan Granules	68.034
		2	Amlodipine Besilate	5.10
Telmisartan and Amlodipine Tablets	1 Number	1	Telmisartan Granules	136.067

80/5mg Each uncoated tablets contains : Telmisartan 80 mg Telmisartan 80 mg equivalent to Telmisartan granules 134.72mg Amlodipine Besilate equivalent to Amlodipine USP 5mg		2	Amlodipine Besilate	5.10

RA may take appropriate action as per the decision of Norms Committee.

30	**Case No.:228/6/82-ALC4/2019**	Party Name:AMI ORGANICS PVT LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00454/AM20/	RLA File :52/24/040/00059/AM18/	Lic.No/Date:5210042473 01.01.2018	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Surat.

31	**Case No.:250/6/82-ALC4/2019**	Party Name:MELOG SPECIALITY CHEMICALS PVT. LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00476/AM20/	RLA File :03/95/040/00823/AM18/	Lic.No/Date:0310818189 03.01.2018	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 3/82-ALC4/2019 dated 05.07.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
MR-3 (2,4,6-TRI [(2,4-DIHYDROXY 3 METHYL) PHENYL] 1,3,5-TRIAZINE	1 kg	1	2 METHYL RESORCINOL	1.140 kg
		2	CYANURIC CHLORIDE	0.479 kg
		3	SULFOLANE	1.80 kg

RA may take appropriate action as per the decision of Norms Committee.

32	**Case No.:224/6/82-ALC4/2019**	Party Name:SHREE GANESH REMEDIES PVT.LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00450/AM20/	RLA File :34/24/040/00340/AM18/	Lic.No/Date:3410043947 09.03.2018	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 5/82-ALC4/2019 dated 02.08.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
Di Methyl Amino Propyl Chloride Hydrochloride-65% solution in water (DMPC 65%)	1 kg	1	1-Bromo-3-Chloro Propane	0.72 kg

RA may take appropriate action as per the decision of Norms Committee.

33	**Case No.:198/6/82-ALC4/2019**	Party Name:ARIHANTANAM LIFECARE PVT. LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00424/AM20/	RLA File :52/24/040/00018/AM19/	Lic.No/Date:5210042636 09.05.2018	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
ARTEMETHER	1 kg	1	ARTEMISININ	1.04 kg

RA concerned may take further necessary action as per above decision of NC.

34	**Case No.:200/6/82-ALC4/2019**	Party Name:GULBRANDSEN CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00426/AM20/	RLA File :34/24/040/00366/AM18/	Lic.No/Date:3410044185 29.05.2018	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 9/82-ALC4/2018 , dated 18.09.2018, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
30% DEZ in Toluene	1 kg	1	Aluminium Grit / Granules	0.10 kg
		2	Zinc Chloride	0.414 kg

RA concerned may take further necessary action as per above decision of NC.

35	**Case No.:222/6/82-ALC4/2019**	Party Name:NOCIL LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00448/AM20/	RLA File :03/95/040/00482/AM19/	Lic.No/Date:0310823440 30.08.2018	

Decision: The Committee considered the cases as per agenda and in the light of earlier decisions taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019 and 5/AM20 dated 02.08.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
N-(Cyclohexylthio-) phthalimide Our Brand Name :- PILGARD PVI	1 kg	1	Phthalic Anyhdride (PAN)	0.603 kg
		2	DICYCLOHEXYL DISULPHIDE (DCDS)	0.486 kg
		3	CAUSTIC POTASH FLAKES (Potassium Hydroxide) (KOH)	0.233 kg

RA may take appropriate action as per the decision of Norms Committee.

36	**Case No.:201/6/82-ALC4/2019**	Party Name:DEEPAK NITRITE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00427/AM20/	RLA File :34/24/040/00257/AM18/	Lic.No/Date:3410044637 25.10.2018	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: (i) Complete 4E with all technical details chemistry, molecular weight, stoichiometric reaction and % of yield at every stage.			

37	**Case No.:202/6/82-ALC4/2019**	Party Name:TIDE INDUSTRIES	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00428/AM20/	RLA File :34/24/040/00276/AM19/	Lic.No/Date:3410044740 06.12.2018	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Aldehyde C-12 MNA	1 kg	1	C-11 Alcohol	1.92 kg

RA may take appropriate action as per the decision of Norms Committee.

38	**Case No.:138/6/82-ALC4/2019**	Party Name:KLJ PLASTICIZERS LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00364/AM20/	RLA File :05/23/040/00513/AM19/	Lic.No/Date:0510409721 21.02.2019	

Decision: The Committee considered case as per agenda and as per earlier decision taken by NC in its 8/82-ALC4/2018 meeting dated 31.08.2018, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
KANATOL - 8080	1 kg	1	TERE PHTHALIC ACID	0.447 kg
		2	2-ETHYL HEXANOL	0.740 kg
		3	HDPE GRANULES	Relevant as per packing policy

RA concerned may take further necessary action as per above decision of NC

39	**Case No.:195/6/82-ALC4/2019**	Party Name:SUPRIYA LIFESCIENCE LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00421/AM20/	RLA File :03/95/040/01203/AM19/	Lic.No/Date:0310827249 22.02.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
RACTOPAMINE Hcl	1 kg	1	OCTOPAMINE Hcl	0.833 kg
		2	RASPBERRY KETONE	0.700 kg
		3	PALLADIUM ON CHARCOAL 5%	0.015 kg

RA concerned may take further necessary action as per above decision of NC.

40	**Case No.:136/6/82-ALC4/2019**	Party Name:ENCUBE ETHICALS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00362/AM20/	RLA File :03/94/040/01057/AM19/	Lic.No/Date:0310827548 08.03.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

41	**Case No.:133/6/82-ALC4/2019**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00359/AM20/	RLA File :03/95/040/01320/AM19/	Lic.No/Date:0310827769 18.03.2019	Defer Date:

Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm:

(i) Complete 4E with all technical details chemistry, molecular weight, stoichiometric reaction and % of yield at every stage.
(ii) Percentage wastage from crude to finished item.

42	**Case No.:135/6/82-ALC4/2019**	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00361/AM20/	RLA File :03/95/040/00745/AM16/	Lic.No/Date:0310827841 20.03.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 15/82-ALC4/2018 dated 22.03.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
N-DECYL BROMIDE (1-Bromodecane)	1 kg	1	DECYL ALCOHOL (1-DECANOL, N-DECYL ALCOHOL)	0.794 kg
		2	HYDROBROMIC ACID 48%	0.848 kg

RA may take appropriate action as per the decision of Norms Committee.

43	**Case No.:132/6/82-ALC4/2019**	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00358/AM20/	RLA File :03/95/040/00907/AM15/	Lic.No/Date:0310827961 27.03.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
6-BROMOHEXYLTRIMETHYL AMMONIUM BROMIDE	1 kg	1	1,6 HEXANDIOL	1.233 kg
		2	HYDROBROMIC ACID 48%	3.53 kg

RA concerned may take further necessary action as per above decision of NC.

44	**Case No.:172/6/82-ALC4/2019**	Party Name:CARENOW MEDICAL PVT LTD,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00398/AM20/	RLA File :32/24/040/00062/AM19/	Lic.No/Date:3210078903 01.04.2019	Defer Date:

Decision: New Case. The Committee considered the case as per agenda in the presence of technical experts and it was decided to forward a copy of application to DIPP for obtaining its comments.

45	**Case No.:191/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00417/AM20/	RLA File :03/94/040/01149/AM19/	Lic.No/Date:0310828058 01.04.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Quantity allowed in mg/tablet
Telmisartan and Amlodipine Tablets 40/10mg Each uncoated tablets contains : Telmisartan 40 mg Telmisartan 40 mg equivalent to Telmisartan granules 67.36mg/ Amlodipine Besilate equivalent to Amlodipine USP 10mg	1 Number	1	Telmisartan Granules	68.034
		2	Amlodipine Besilate	10.20
Telmisartan and Amlodipine Tablets 80/10mg Each uncoated tablets contains : Telmisartan 80 mg Telmisartan 80 mg equivalent to Telmisartan granules 134.72mg Amlodipine Besilate equivalent to Amlodipine USP 10mg	1 Number	1	Telmisartan Granules	136.067
		2	Amlodipine Besilate	10.20
Telmisartan and Amlodipine Tablets 40/5mg Each uncoated tablets contains : Telmisartan 40 mg Telmisartan 40 mg equivalent to Telmisartan granules 67.36mg Amlodipine Besilate equivalent to Amlodipine USP 5mg	1 Number	1	Telmisartan Granules	68.034
		2	Amlodipine Besilate	5.10
Telmisartan and Amlodipine Tablets 80/5mg Each uncoated tablets contains : Telmisartan 80 mg Telmisartan 80 mg equivalent to Telmisartan granules 134.72mg Amlodipine Besilate equivalent to Amlodipine USP 5mg	1 Number	1	Telmisartan Granules	136.067
		2	Amlodipine Besilate	5.10

RA may take appropriate action as per the decision of Norms Committee.

46	**Case No.:131/6/82-ALC4/2019**	Party Name:MALWA OXYGEN & INDUSTRIAL GASES PVT.LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00357/AM20/	RLA File :56/24/040/00037/AM19/	Lic.No/Date:5610005601 06.05.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

47	**Case No.:134/6/82-ALC4/2019**	Party Name:MALWA OXYGEN & INDUSTRIAL GASES PVT.LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00360/AM20/	RLA File :56/24/040/00002/AM20/	Lic.No/Date:5610005600 06.05.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

48	**Case No.:194/6/82-ALC4/2019**	Party Name:ETERNIS FINE CHEMICALS LIMITED,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00420/AM20/	RLA File :03/94/040/00023/AM20/	Lic.No/Date:0310828815 07.05.2019	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: (i) Complete 4E with all technical details chemistry, molecular weight, stoichiometric reaction and % of yield at every stage.			

49	**Case No.:251/6/82-ALC4/2019**	Party Name:INDO AMINES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00477/AM20/	RLA File :03/94/040/00097/AM20/	Lic.No/Date:0310828974 13.05.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
COCO AMINE DISTILLED (Purity 99.5%)	1 kg	1	COCO AMINE DISTILLED (PURITY 98%)	1.02 kg

RA may take appropriate action as per the decision of Norms Committee.

50	**Case No.:252/6/82-ALC4/2019**	Party Name:SPC LIFE SCIENCES PVT. LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00478/AM20/	RLA File :34/24/040/00053/AM20/	Lic.No/Date:3410045166 21.05.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 3/82-ALC4/2019 dated 05.07.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
CHLOROHEXAN-2-ONE	1 kg	1	1-BROMO-3-CHLOROPROPANE CLEAR LIQUID	2.05 kg
		2	METHYL ACETO ACETATE CLEAR COLOURLESS TO LIGHT YELLOW LIQUID	1.65 kg
		3	SODIUM METHOXIDE WHITE POWDER	1.25 kg

RA may take appropriate action as per the decision of Norms Committee.

51	**Case No.:1/6/82-ALC4/2019**	Party Name:MALLADI DRUGS & PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00227/AM20/	RLA File :04/24/040/00048/AM20/	Lic.No/Date:0410165665 31.05.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Chennai.

52	**Case No.:2/6/82-ALC4/2019**	Party Name:VISION DRUGS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00228/AM20/	RLA File :09/24/040/00093/AM20/	Lic.No/Date:0910067615 31.05.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

53	**Case No.:3/6/82-ALC4/2019**	Party Name:OPTIMUS DRUGS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00229/AM20/	RLA File :09/24/040/00104/AM20/	Lic.No/Date:0910067616 31.05.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
RIFAXIMIN Ph.Eur	1kg	1	RIFAMYCIN-O	1.52 kg

RA concerned may take further necessary action as per above decision of NC.

54	**Case No.:4/6/82-ALC4/2019**	Party Name:DIVIS LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00230/AM20/	RLA File :09/24/040/00101/AM20/	Lic.No/Date:0910067620 31.05.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

55	**Case No.:5/6/82-ALC4/2019**	Party Name:DIVIS LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00231/AM20/	RLA File :09/24/040/00100/AM20/	Lic.No/Date:0910067621 31.05.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 10/82-ALC4/2018 dated 16.10.2018, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
B-WING (L-VALINE CYCLIC UREA)	1 kg	1	L-VALINE	1.837 kg
		2	METHYL CHLORO FORMATE	2.25 kg
		3	ACRYLONITRILE	0.95 kg
		4	CAUSTIC POTASH FLAKES	4.055 kg
		5	METHYLENE CHLORIDE	2.25 kg
		6	ISO PROPYL ALCOHOL	0.92 kg

RA may take appropriate action as per the decision of Norms Committee.

56	**Case No.:6/6/82-ALC4/2019**	Party Name:BIOLOGICAL E LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00232/AM20/	RLA File :09/24/040/00102/AM20/	Lic.No/Date:0910067622 03.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
DAPTOMYCIN FOR INJCTION 500 MG PER VIAL	1 Number	1	DAPTOMYCIN	550 mg / 5 ml vial

RA may take appropriate action as per the decision of Norms Committee

57	**Case No.:7/6/82-ALC4/2019**	Party Name:BIOLOGICAL E LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00233/AM20/	RLA File :09/24/040/00062/AM20/	Lic.No/Date:0910067623 03.06.2019	Defer Date:

Decision: New Case. The Committee considered the case as per agenda in the presence of technical experts and it was decided to forward a copy of application to DBT for obtaining its comments.

58	**Case No.:8/6/82-ALC4/2019**	Party Name:PANACEA BIOTEC LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00234/AM20/	RLA File :05/24/040/00130/AM20/	Lic.No/Date:0510410795 03.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
ALPHADOL CAPSULES (EACH SOFT GELATIN CAPSULE CONTAINS: ALFACALCIDOL 0.25 MCG)	3000000 Number	1	ALFACALCIDOL	1.050 gram

The Committee allowed the above norms on one time basis and no repeat norms is allowed.
RA concerned may take further necessary action as per above decision of NC.

59	**Case No.:9/6/82-ALC4/2019**	Party Name:RAJASTHAN ANTIBIOTICS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00235/AM20/	RLA File :05/24/040/00108/AM20/	Lic.No/Date:0510410798 03.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from CLA, New Delhi.

60	**Case No.:10/6/82-ALC4/2019**	Party Name:ADCOCK INGRAM LTD,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00236/AM20/	RLA File :07/24/040/00039/AM20/	Lic.No/Date:0710115001 03.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Bangalore.			

61	**Case No.:11/6/82-ALC4/2019**	Party Name:NECTAR LIFESCIENCES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00237/AM20/	RLA File :22/24/040/00017/AM20/	Lic.No/Date:2210016174 03.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Cefazolin Sodium Sterile	1 kg	1	Cefazolin Acid	0.989 kg
		2	Acetone	0.515 kg
		3	Activated Carbon	0.020 kg

RA may take appropriate action as per the decision of Norms Committee

62	**Case No.:12/6/82-ALC4/2019**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00238/AM20/	RLA File :31/83/040/00040/AM20/	Lic.No/Date:3110067438 03.06.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 12/82-ALC4/2018 dated 12.12..2018, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No	Import Items	Qty.
GAMMA BUTYROLACTONE	1 kg	1.	1,4 BUTANEDIOL	1.16 kg
		2.	GBL CATAYLYST	0.001 kg

RA may take appropriate action as per the decision of Norms Committee.

63	**Case No.:13/6/82-ALC4/2019**	Party Name:ALEMBIC PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00239/AM20/	RLA File :34/24/040/00081/AM20/	Lic.No/Date:3410045187 04.06.2019	

Decision: The Committee considered case as per agenda and as per earlier decision taken by NC in its 13/82-ALC4/2018 meeting dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-

Export product	Qty.	Sl. No.	Import items	Qty.
Temazepam Caps Usp 7.5 mg (net content of active ingredients = 5.625 kgs)	1 Number	1	Temazepam USP	7.65 mg /7.5 mg tablet
Temazepam Caps Usp 15 mg (net content of active ingredients = 180 kgs)	1 Number	2	Temazepam USP	15.30 mg /15 mg tablet
Temazepam Caps Usp 30 mg (net content of active ingredients = 468 kgs)	1 Number	3	Temazepam USP	30.6 mg /30 mg tablet

RA concerned may take further necessary action as per above decision of NC

64	**Case No.:14/6/82-ALC4/2019**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00240/AM20/	RLA File :03/94/040/00176/AM20/	Lic.No/Date:0310829437 06.06.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

65	**Case No.:15/6/82-ALC4/2019**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00241/AM20/	RLA File :03/94/040/00177/AM20/	Lic.No/Date:0310829438 06.06.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 14/82-ALC4/2018 dated 14.02.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
VILDAGLIPTIN	1 kg	1	3-Amino-1-adamantanol	0.904 kg

RA may take appropriate action as per the decision of Norms Committee.

66	**Case No.:16/6/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00242/AM20/	RLA File :03/94/040/00178/AM20/	Lic.No/Date:0310829440 06.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export product	Qty.	Import items	Qty.
1	Alclometasone Dipropionate USP Cream 0.05% 15gm (Pack Size 15gm)	80000.000 Pack	Alclometasone Dipropionate USP	5.317 kg
2	Alclometasone Dipropionate USP Cream 0.05% 45gm (Pack Size 45gm)	50000.000 Pack		
3	Alclometasone Dipropionate USP Cream 0.05% 60gm (Pack Size 60gm)	40000.000 Pack		
4	Alclometasone Dipropionate Ointment 0.05% 15gm (Pack Size 15gm)	50000.000 Pack		
5	Alclometasone Dipropionate Ointment 0.05% 45gm (Pack Size 45gm)	45000.000 Pack		
6	Alclometasone Dipropionate Ointment 0.05% 60gm (Pack Size 60gm)	30000.000 Pack		

RA concerned may take further necessary action as per above decision of NC.

67	**Case No.:17/6/82-ALC4/2019**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00243/AM20/	RLA File :03/94/040/00036/AM20/	Lic.No/Date:0310829443 06.06.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
Diclofenac Sodium	1 kg	1.	Acetic Acid	1.25 kg
		2.	Methanol	1.00 kg
		3.	2,6 Dichlorophenol	1.521 kg
		4.	Toluene	1.995 kg
		5.	Potassium Carbonate	1.00 kg
		6.	Aniline	1.198 kg
		7.	Sodium Methoxide	0.795 kg
		8.	Sodium Hydroxide Flakes	0.285 kg
		9.	Isopropyl Alcohol	2.040 kg
		10.	Dimethyl Formamide	0.469 kg

RA may take appropriate action as per the decision of Norms Committee.

68	**Case No.:18/6/82-ALC4/2019**	Party Name:SMILAX LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00244/AM20/	RLA File :09/24/040/00103/AM20/	Lic.No/Date:0910067628 06.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.

69	**Case No.:19/6/82-ALC4/2019**	Party Name:S V LABS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00245/AM20/	RLA File :09/24/040/00086/AM20/	Lic.No/Date:0910067629 06.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.

70	**Case No.:20/6/82-ALC4/2019**	Party Name:SHREE JAYA LABORATORIES PVT LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00246/AM20/	RLA File :09/24/040/00096/AM20/	Lic.No/Date:0910067630 06.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
5-DIFLUOROMETHOXY-2MERCAPTO-1H-BENZIMIDAZOLE	1 kg	1	ACETONITRIL	0.17 kg
		2	CHLOROFORM	0.18 kg
		3	SODA ASH	3.03 kg
		4	PARACETMOL	1.435 kg
		5	CARBON DI SULFIDE	0.70 kg
		6	FREON GAS	0.715 kg

RA may take appropriate action as per the decision of Norms Committee

71	**Case No.:21/6/82-ALC4/2019**	Party Name:SHREE JAYA LABORATORIES PVT LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00247/AM20/	RLA File :09/24/040/00097/AM20/	Lic.No/Date:0910067631 06.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
2-HYDROXY METHYL-3,5-DIMETHYL 4-METHOXY PYRIDINE HYDROCHLORIDE	1 kg	1	3,5 LUTIDINE	1.04 kg
		2	CHLOROFORM	3.20 kg
		3	METHYLENE DICHLORIDE	2.00 kg
		4	AMMONIUM PER SULPHATE	1.80 kg
		5	ISO PROPYL ALCOHOL	1.00 kg

RA may take appropriate action as per the decision of Norms Committee

72	**Case No.:22/6/82-ALC4/2019**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00248/AM20/	RLA File :03/94/040/00937/AM19/	Lic.No/Date:0310829454 06.06.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 3/82-ALC4/2019 dated 05.07.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
Ciprofloxacin Hydrochloride	1 kg	1	Ethyl 3 Cyclopropylamino-2(2,4 Dichloro-5 Fluorobenzoyl) Acrylate	1.294 kg
		2	Caustic Soda Flakes	0.35 kg
		3	Toluene	0.123 kg
		4	Anhydrous Piperazine	0.39 kg

RA may take appropriate action as per the decision of Norms Committee.

73	**Case No.:23/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00249/AM20/	RLA File :03/95/040/00015/AM20/	Lic.No/Date:0310829466 07.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

74	**Case No.:24/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00250/AM20/	RLA File :03/95/040/00021/AM20/	Lic.No/Date:0310829479 07.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

75	**Case No.:25/6/82-ALC4/2019**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00251/AM20/	RLA File :09/24/040/00098/AM20/	Lic.No/Date:0910067641 07.06.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

76	**Case No.:26/6/82-ALC4/2019**	Party Name:MSN LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00252/AM20/	RLA File :09/24/040/00113/AM20/	Lic.No/Date:0910067642 07.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Exemestane Tablets 25 mg	1 Number	1	EXEMESTANE	25.50 mg / 25 mg tablet

RA concerned may take further necessary action as per above decision of NC.

77	**Case No.:27/6/82-ALC4/2019**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00253/AM20/	RLA File :03/94/040/01134/AM19/	Lic.No/Date:0310829511 10.06.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

78	**Case No.:28/6/82-ALC4/2019**	Party Name:O C SPECIALITIES PVT.LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00254/AM20/	RLA File :03/95/040/00227/AM20/	Lic.No/Date:0310829526 10.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
2,3 DICHLORO PYRIDINE	1 kg	1	3 AMINO PYRIDINE	1.00 kg
		2	HYDROGEN PEROXIDE (50 % CONCENTRATION)	0.637 kg
		3	SODIUM NITRITE	0.687 kg
		4	CAUSTIC SODA LYE (SODIUM HYDOXIDE LYE)	6.33 kg

RA concerned may take further necessary action as per above decision of NC.

79	**Case No.:29/6/82-ALC4/2019**	Party Name:ONEIRO CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00255/AM20/	RLA File :34/24/040/00082/AM20/	Lic.No/Date:3410045199 10.06.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
4,5,6,7-TETRAHYDRO THIENO (3,2,C) PYRIDINE HYDROCHLORIDE	1 kg	1	Thiophene 2 Ethylamine	0.87 kg
		2	Methanol	1.49 kg
		3	Methyene Chloride	0.79 kg

RA concerned may take further necessary action as per above decision of NC.

80	**Case No.:30/6/82-ALC4/2019**	Party Name:TIDE INDUSTRIES	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00256/AM20/	RLA File :34/24/040/00083/AM20/	Lic.No/Date:3410045200 10.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Vadodara.

81	**Case No.:31/6/82-ALC4/2019**	Party Name:GITANJALI CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00257/AM20/	RLA File :03/94/040/01070/AM19/	Lic.No/Date:0310829535 11.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

82	**Case No.:32/6/82-ALC4/2019**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00258/AM20/	RLA File :09/24/040/00111/AM20/	Lic.No/Date:0910067648 11.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Tigecycline Powder for Solution for Infusion,(Lyophilized) 50mg/vial, 5ml Vial	396826 Number	1	Tigecycline	21.82 kg
		2	Glass Vials	Relevant as per Packing Policy
		3	Rubber Stoppers	
		4	Flip off Seals	

RA concerned may take further necessary action as per above decision of NC.

83	**Case No.:36/6/82-ALC4/2019**	Party Name:NOVEL NUTRIENTS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00262/AM20/	RLA File :07/24/040/00056/AM20/	Lic.No/Date:0710115041 11.06.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

84	**Case No.:33/6/82-ALC4/2019**	Party Name:ASHISH LIFE SCIENCE PVT.LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00259/AM20/	RLA File :03/94/040/00197/AM20/	Lic.No/Date:0310829569 12.06.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

85	**Case No.:34/6/82-ALC4/2019**	Party Name:DIPS BIOSCIENCE PVT.LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00260/AM20/	RLA File :03/94/040/00199/AM20/	Lic.No/Date:0310829573 12.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

86	**Case No.:35/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00261/AM20/	RLA File :03/95/040/00225/AM20/	Lic.No/Date:0310829588 12.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

87	**Case No.:37/6/82-ALC4/2019**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PVT.LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00263/AM20/	RLA File :31/83/040/00042/AM20/	Lic.No/Date:3110067445 12.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Guaiacol	1 kg	1	Phenol	1.012 kg
		2	Methanol	0.39 kg
		3	Hydrogen Peroxide PURITY 60%	0.687 kg
		4	Acetone (Solvent)	0.14 kg

RA may take appropriate action as per the decision of Norms Committee.

88	**Case No.:38/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00264/AM20/	RLA File :03/95/040/00223/AM20/	Lic.No/Date:0310829590 12.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

89	**Case No.:39/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00265/AM20/	RLA File :03/95/040/00222/AM20/	Lic.No/Date:0310829591 12.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

90	**Case No.:40/6/82-ALC4/2019**	Party Name:NECTAR LIFESCIENCES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00266/AM20/	RLA File :22/24/040/00101/AM19/	Lic.No/Date:2210016183 12.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

91	**Case No.:41/6/82-ALC4/2019**	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00267/AM20/	RLA File :09/24/040/00107/AM20/	Lic.No/Date:0910067652 12.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

92	**Case No.:43/6/82-ALC4/2019**	Party Name:SARACA LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00269/AM20/	RLA File :09/24/040/00117/AM20/	Lic.No/Date:0910067656 12.06.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import Items	Qty.
GABAPENTIN	1 kg	1	1,1 CYCLOHEXANE DI ACETIC ACID MONOAMIDE (CAM)	1.630 kg

RA concerned may take further necessary action as per above decision of NC.

93	**Case No.:46/6/82-ALC4/2019**	Party Name:PI INDUSTRIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00272/AM20/	RLA File :13/24/040/00151/AM20/	Lic.No/Date:1310049313 12.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
HYPE Chemical Name: Methyl 1-(3-chloropyridin-2-yl)-3-hydroxymethyl-1H-pyrazole-5-carboxylate	1 kg	1	3-Chloro-2-Hydrazinopyridine	0.670 kg
		2	2-methyl-5-ethyl pyridine	0.0224 kg
		3	Epichlorohydrin	0.545 kg
		4	Methyl oxalyl chloride	0.672 kg
		5	Tetrahydrofurfuryl alcohol	0.320 kg

RA may take appropriate action as per the decision of Norms Committee

94	**Case No.:47/6/82-ALC4/2019**	Party Name:PI INDUSTRIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00273/AM20/	RLA File :13/24/040/00150/AM20/	Lic.No/Date:1310049314 12.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
2-methyl-1-methylthio-2-propanamine (SAA)	1 kg	1	2-Amino-2-Methyl-1-Propanol (AMP)	0.865 kg

RA concerned may take further necessary action as per above decision of NC.

95	**Case No.:48/6/82-ALC4/2019**	Party Name:PI INDUSTRIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00274/AM20/	RLA File :13/24/040/00149/AM20/	Lic.No/Date:1310049315 12.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
2-CYANIMINO 1,3 THIAZOLIDIN (CIT)	1 kg	1	Cysteamine Hydrochloride 95% Min	1.04 kg
		2	Dimethyl N-Cyanodithioimino Carbonate (CCITM)	1.28 kg

RA may take appropriate action as per the decision of Norms Committee

96	**Case No.:193/6/82-ALC4/2019**	Party Name:ALKYL AMINES CHEMICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00419/AM20/	RLA File :03/94/040/00001/AM20/	Lic.No/Date:0310829582 12.06.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 12/82-ALC4/2018 dated 12.12..2018, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
2ETHYLHEXYLAMINE	1 kg	1	2ETHYLHEXANOL	1.011 kg

RA may take appropriate action as per the decision of Norms Committee.

97	**Case No.:44/6/82-ALC4/2019**	Party Name:DIVIS LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00270/AM20/	RLA File :09/24/040/00118/AM20/	Lic.No/Date:0910067663 13.06.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

98	**Case No.:45/6/82-ALC4/2019**	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00271/AM20/	RLA File :09/24/040/00114/AM20/	Lic.No/Date:0910067664 13.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.

99	**Case No.:58/6/82-ALC4/2019**	Party Name:WINDLAS HEALTH CARE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00284/AM20/	RLA File :61/24/040/00001/AM20/	Lic.No/Date:6110001597 13.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
PIROXICAM CAPSULE 10 mg	1 Number	1	PIROXICAM	10.2 mg / 10 mg capsule
PIROXICAM CAPSULE 20 mg	1 Number	1	PIROXICAM	20.4 mg / 20 mg capsule

RA may take appropriate action as per the decision of Norms Committee

100	**Case No.:59/6/82-ALC4/2019**	Party Name:WINDLAS HEALTH CARE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00285/AM20/	RLA File :61/24/040/00002/AM20/	Lic.No/Date:6110001598 13.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Acyclovir Capsules 200 mg Anti Viral Drug	1 Number	1	Acyclovir	204 mg / 200 mg capsule

RA may take appropriate action as per the decision of Norms Committee

101	**Case No.:42/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00268/AM20/	RLA File :03/95/040/00110/AM20/	Lic.No/Date:0310829637 14.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

102	**Case No.:49/6/82-ALC4/2019**	Party Name:DHANUKA LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00275/AM20/	RLA File :05/23/040/00104/AM20/	Lic.No/Date:0510410949 14.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from CLA, New Delhi.

103	**Case No.:50/6/82-ALC4/2019**	Party Name:VISION DRUGS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00276/AM20/	RLA File :09/24/040/00121/AM20/	Lic.No/Date:0910067669 14.06.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

104	**Case No.:51/6/82-ALC4/2019**	Party Name:SYNNAT PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00277/AM20/	RLA File :02/24/040/00044/AM20/	Lic.No/Date:0210209260 17.06.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Noscapine BP USP Ph.Eur JP CP / Noscapine Hydrochloride BP Ph.Eur	1 kg	1	Noscapine Crude Content 95%	1.10 kg

RA concerned may take further necessary action as per above decision of NC.

105	**Case No.:52/6/82-ALC4/2019**	Party Name:DECCAN NUTRACEUTICALS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00278/AM20/	RLA File :02/24/040/00042/AM20/	Lic.No/Date:0210209261 17.06.2019	Defer Date:

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information:

(i) Certificate of Analysis (CoA) of import item from foreign supplier.

106	**Case No.:53/6/82-ALC4/2019**	Party Name:KAIRAV CHEMOFARBE INDUSTRIES LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00279/AM20/	RLA File :03/94/040/00201/AM20/	Lic.No/Date:0310829703 17.06.2019	Defer Date:
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information: (i) Certificate of Analysis (CoA) of import item from foreign supplier. (ii) Certificate of Analysis (CoA) of export product.			

107	**Case No.:54/6/82-ALC4/2019**	Party Name:COVALENT LABORATORIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00280/AM20/	RLA File :09/24/040/00130/AM20/	Lic.No/Date:0910067671 18.06.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

108	**Case No.:55/6/82-ALC4/2019**	Party Name:CADILA HEALTHCARE LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00281/AM20/	RLA File :08/24/040/00094/AM20/	Lic.No/Date:0810145530 18.06.2019	

Decision: The Committee considered case as per agenda and deliberated on the matter in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.
1	ISOSORBIDE DINITRATE TABLETS USP 5 MG (ACTIVE INGREDIENT : DILUTED ISOSORBIDE DINITRATE USP EQUIVALENT TO ISOSORBIDE DINITRATE USP - NET WT. 15.980 KGS)	1 Number
2	ISOSORBIDE DINITRATE TABLETS USP 10 MG (ACTIVE INGREDIENT : DILUTED ISOSORBIDE DINITRATE USP EQUIVALENT TO ISOSORBIDE DINITRATE USP - NET WT. 92.790 KGS)	1 Number
3	ISOSORBIDE DINITRATE TABLETS USP 20 MG (ACTIVE INGREDIENT : DILUTED ISOSORBIDE DINITRATE USP EQUIVALENT TO ISOSORBIDE DINITRATE USP - NET WT. 212.812 KGS)	1 Number
4	ISOSORBIDE DINITRATE TABLETS USP 30 MG (ACTIVE INGREDIENT : DILUTED ISOSORBIDE DINITRATE USP EQUIVALENT TO ISOSORBIDE DINITRATE USP - NET WT. 153.162 KGS)	1 Number
5	ISOSORBIDE DINITRATE TABLETS USP 40 MG (ACTIVE INGREDIENT : DILUTED ISOSORBIDE DINITRATE USP EQUIVALENT TO ISOSORBIDE DINITRATE USP - NET WT. 12.420 KGS)	1 Number

S.NO.	Import Items	For export of 1 Number of tablet (Quantity in mg)

		5 mg	10 mg	20 mg	30 mg	40 mg
1	DILUTED ISOSORBIDE DINITRATE USP	12.75	25.00	50.00	75.00	100.00
2	LACTOSE MONOHYDRATE NF	48.16	96.55	71.00	46.43	88.39
3	SODIUM STARCH GLYCOLATE TYPE A NF/JP	5.23	10.45	10.45	10.45	4.375
4	MICROCRYSTALLINE CELLULOSE (AVICEL PH 200) NF/PH.EUR	11.00	22.00	22.00	22.00	52.50
5	MAGNESIUM STEARATE PH.EUR/NF/JP	1.10	2.20	2.20	2.20	3.50

RA concerned may take further necessary action as per above decision of NC.

109	**Case No.:56/6/82-ALC4/2019**	Party Name:SOLARA ACTIVE PHARMA SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00282/AM20/	RLA File :04/24/040/00050/AM20/	Lic.No/Date:0410165732 18.06.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

110	**Case No.:57/6/82-ALC4/2019**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00283/AM20/	RLA File :03/95/040/00269/AM20/	Lic.No/Date:0310829756 18.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
ZINC DIACRYLATE(QUREACC ZDA)	1 kg	1	ACRYLIC ACID	0.744 kg
		2	ZINC OXIDE	0.425 kg

RA may take appropriate action as per the decision of Norms Committee.

111	**Case No.:60/6/82-ALC4/2019**	Party Name:TIDE INDUSTRIES	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00286/AM20/	RLA File :34/24/040/00101/AM20/	Lic.No/Date:3410045217 18.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Vadodara.

112	**Case No.:61/6/82-ALC4/2019**	Party Name:ASTRAL STERITECH PVT. LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00287/AM20/	RLA File :34/24/040/00102/AM20/	Lic.No/Date:3410045218 19.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Vadodara.			

113	**Case No.:62/6/82-ALC4/2019**	Party Name:DR. REDDYS LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00288/AM20/	RLA File :09/24/040/00122/AM20/	Lic.No/Date:0910067680 19.06.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

114

Case No.:63/6/82-ALC4/2019	Party Name:AARTI DRUGS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
HQ File :01/82/050/00289/AM20/	RLA File :03/94/040/00880/AM19/	Lic.No/Date:0310829807 20.06.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 3/82-ALC4/2019 dated 05.07.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
Ciprofloxacin Hydrochloride	1 kg	1	Ethyl 3 Cyclopropylamino-2(2,4 Dichloro-5 Fluorobenzoyl) Acrylate	1.294 kg
		2	Caustic Soda Flakes	0.35 kg
		3	Sulphuric Acid (98%)	Not importable
		4	Toluene	0.123 kg
		5	Anhydrous Piperazine	0.39 kg

RA may take appropriate action as per the decision of Norms Committee.

115

Case No.:64/6/82-ALC4/2019	Party Name:PRO-LIFE BIO-CHEMICAL INDUSTRIES (P) LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
HQ File :01/82/050/00290/AM20/	RLA File :03/95/040/00215/AM20/	Lic.No/Date:0310829817 20.06.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl.No.	Import items	Qty.
1-METHYLAMINO-4-BROMO ANTHRAQUINONE	1 kg	1	1-NITROANTHRAQUINONE	1.234 kg

RA may take appropriate action as per the decision of Norms Committee.

116	**Case No.:65/6/82-ALC4/2019**	Party Name:SMS PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00291/AM20/	RLA File :09/24/040/00144/AM20/	Lic.No/Date:0910067683 20.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

117	**Case No.:66/6/82-ALC4/2019**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PVT.LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00292/AM20/	RLA File :31/83/040/00044/AM20/	Lic.No/Date:3110067449 20.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Guaiacol	1 kg	1	Phenol	1.012 kg
		2	Methanol	0.39 kg
		3	Hydrogen Peroxide PURITY 60%	0.687 kg
		4	Acetone (Solvent)	0.14 kg

RA may take appropriate action as per the decision of Norms Committee.

118	**Case No.:67/6/82-ALC4/2019**	Party Name:ASTRAL STERITECH PVT. LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00293/AM20/	RLA File :34/24/040/00100/AM20/	Lic.No/Date:3410045222 20.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Vadodara.			

119	**Case No.:68/6/82-ALC4/2019**	Party Name:THINQ PHARMA CRO LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00294/AM20/	RLA File :03/95/040/00274/AM20/	Lic.No/Date:0310829823 21.06.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 3/82-ALC4/2019 dated 05.07.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
G-101 (All Trans Retinoic Acid,1-Hydroxy-3,3-dimethyl-2-Butanone Ester)	1 kg	1	Tretinoin (All Trans Retinoic Acid)	1.00 kg
		2	1-Chloro Pinacolone	0.469 kg
		3	Cesium Carbonate	1.135 kg

RA may take appropriate action as per the decision of Norms Committee.

120	**Case No.:69/6/82-ALC4/2019**	Party Name:ALTA LABORATORIES LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00295/AM20/	RLA File :03/94/040/00239/AM20/	Lic.No/Date:0310829833 21.06.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
SODIUM SALICYLATE	1 kg	1	SALICYLIC ACID	0.88 kg

RA concerned may take further necessary action as per above decision of NC.

121	**Case No.:70/6/82-ALC4/2019**	Party Name:ALTA LABORATORIES LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00296/AM20/	RLA File :03/94/040/00240/AM20/	Lic.No/Date:0310829834 21.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
METHYL SALICYLATE	1 kg	1	SALICYLIC ACID	0.955 kg
		2	METHANOL	0.244 kg

RA concerned may take further necessary action as per above decision of NC

122	**Case No.:73/6/82-ALC4/2019**	Party Name:NATURAL AND ESSENTIAL OILS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00299/AM20/	RLA File :07/24/040/00072/AM20/	Lic.No/Date:0710115086 21.06.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl.No.	Import items	Qty.
Caffeine	10020 kg	1	Crude Caffeine (decaffeination from green coffee)Purity 53.38%	17600 kg
Coffee Extracts	6150 kg			

RA concerned may take further necessary action as per above decision of NC.

123	**Case No.:71/6/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00297/AM20/	RLA File :03/94/040/00225/AM20/	Lic.No/Date:0310829872 24.06.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 1/82-ALC4/2019 dated 03.06.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import items	Qty.
Omeprazole DR Capsules USP 10mg (Pack size 30 tabs) (Net wt. of Sugar Spheres 18 - 20 (SURINERTS) (SUGAR SPHERES USP-NF(850-1000)) is 144.000 Kgs)	120000.000 Packs	1	Sugar Spheres 18 - 20 (SURINERTS) (SUGAR SPHERES USP-NF(850-1000))	60089.21 kg
Omeprazole DR Capsules USP 10mg (Pack size 100 tabs) (Net wt. of Sugar Spheres 18 - 20 (SURINERTS) (SUGAR SPHERES USP-NF(850-1000)) is 259.200 Kgs)	64800.000 Packs			
Omeprazole DR Capsules USP 20mg (Pack size 30 tabs) (Net wt. of Sugar Spheres 18 - 20 (SURINERTS) (SUGAR SPHERES USP-NF(850-1000)) is 432.000 Kgs)	180000.000 Packs			
Omeprazole DR Capsules USP 20mg (Pack size 100 tabs) (Net wt. of Sugar Spheres 18 - 20 (SURINERTS) (SUGAR SPHERES USP-NF(850-1000)) is 2448.000 Kgs)	306000.000 Packs			
Omeprazole DR Capsules USP 20mg (Pack size 1000 tabs) (Net wt. of Sugar Spheres 18 - 20 (SURINERTS) (SUGAR SPHERES USP-NF(850-1000)) is 20664.000 Kgs)	258300.000 Packs			
Omeprazole DR Capsules USP 40mg (Pack size 30 tabs) (Net wt. of Sugar Spheres 18 - 20 (SURINERTS) (SUGAR SPHERES USP-NF(850-1000)) is 892.500 Kgs)	350000.000 Packs			

Omeprazole DR Capsules USP 40mg (Pack size 90 tabs) (Net wt. ofSugar Spheres 18 - 20 (SURINERTS) (SUGAR SPHERES USP-NF(850-1000)) is 5712.010 Kgs)	746668.000 Packs			
Omeprazole DR Capsules USP 40mg (Pack size 100 tabs) (Net wt. of Sugar Spheres 18 - 20 (SURINERTS) (SUGAR SPHERES USP-NF(850-1000)) is 2337.500 Kgs)	275000.000 Packs			
Omeprazole DR Capsules USP 40mg (Pack size 1000 tabs) (Net wt. of Sugar Spheres 18 - 20 (SURINERTS) (SUGAR SPHERES USP-NF(850-1000)) is 27200.000 Kgs)	320000.000 Packs			

RA may take appropriate action as per the decision of Norms Committee.

124	**Case No.:72/6/82-ALC4/2019**	Party Name:BENZO CHEM INDUSTRIES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00298/AM20/	RLA File :03/94/040/00210/AM20/	Lic.No/Date:0310829874 24.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

125	**Case No.:74/6/82-ALC4/2019**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00300/AM20/	RLA File :09/24/040/00147/AM20/	Lic.No/Date:0910067684 24.06.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

126	**Case No.:75/6/82-ALC4/2019**	Party Name:NAARI PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00301/AM20/	RLA File :05/24/040/00172/AM20/	Lic.No/Date:0510411026 24.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from CLA, New Delhi.			

127	**Case No.:76/6/82-ALC4/2019**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00302/AM20/	RLA File :09/24/040/00132/AM20/	Lic.No/Date:0910067687 24.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from CLA, New Delhi.			

128	**Case No.:77/6/82-ALC4/2019**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00303/AM20/	RLA File :09/24/040/00133/AM20/	Lic.No/Date:0910067688 24.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

129	**Case No.:78/6/82-ALC4/2019**	Party Name:INDO AMINES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00304/AM20/	RLA File :03/94/040/00179/AM20/	Lic.No/Date:0310829884 25.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
TALLOW AMINE	1 kg	1	C16 18 FATTY ACID	1.57 kg
		2	NI-CATALYST OR NICKEL METAL	0.001 kg

RA may take appropriate action as per the decision of Norms Committee

130	**Case No.:79/6/82-ALC4/2019**	Party Name:DR. ACHARYA LABORATORIES PVT. LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00305/AM20/	RLA File :03/94/040/00249/AM20/	Lic.No/Date:0310829897 25.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

131	**Case No.:80/6/82-ALC4/2019**	Party Name:DINAKARA LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00306/AM20/	RLA File :09/24/040/00150/AM20/	Lic.No/Date:0910067692 25.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
1-(2,4-Difluoro Phenyl)-2-(1H-1,2,4-triazole-1-yl) Ethanone (Ethanone Derivative)	1 kg	1	1,3-Difluoro Benzene.	0.60 kg

RA may take appropriate action as per the decision of Norms Committee

132	**Case No.:81/6/82-ALC4/2019**	Party Name:VN CREATIVE CHEMICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00307/AM20/	RLA File :03/95/040/00232/AM20/	Lic.No/Date:0310829915 25.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

133	**Case No.:82/6/82-ALC4/2019**	Party Name:KLJ PLASTICIZERS LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00308/AM20/	RLA File :05/23/040/00125/AM20/	Lic.No/Date:0510411049 25.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per SION A-1291 or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
DI-BUTYL PHTHALATE (GRADE-M) (DBP-M) (PACKED IN 2554 NOS. OF HM-HDPE DRUMS MADE OF HDPE GRANULES (21,709.000 KGS. WITHOUT WASTAGE)) (EACH DRUM SHALL WEIGHT 8.5 KG AND STORAGE CAPACITY 235.000 KGS.)	1 kg	1	PHTHALIC ANHYDRIDE	0.56 kg
		2	SABUTOL	0.56 kg
		3	HDPE GRANULES (TOTAL WEIGHT = 22,794.450 KGS.)	Relevant as per packing policy

RA may take appropriate action as per the decision of Norms Committee

134	**Case No.:83/6/82-ALC4/2019**	Party Name:THINQ PHARMA CRO LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00309/AM20/	RLA File :03/95/040/00279/AM20/	Lic.No/Date:0310829925 26.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

135	**Case No.:84/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00310/AM20/	RLA File :03/95/040/00142/AM20/	Lic.No/Date:0310829937 26.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

136	**Case No.:85/6/82-ALC4/2019**	Party Name:SOLARA ACTIVE PHARMA SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00311/AM20/	RLA File :04/24/040/00060/AM20/	Lic.No/Date:0410165773 27.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
IBUPROFEN USP	1 kg	1	ISO BUTYL BENZENE (IBB)	0.887 kg
		2	ACETYL CHLORIDE	0.588 kg
		3	SODIUM METAL	0.219 kg
		4	MANOCHLORO ACETIC ACID	0.919 kg
		5	ISO-PROPYL ALCOHOL	0.250 kg
		6	ISO-PROPYL ALCOHOL	0.250 kg
		7	SODIUM DICHROMATE	0.630 kg

RA may take appropriate action as per the decision of Norms Committee

137	**Case No.:86/6/82-ALC4/2019**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00312/AM20/	RLA File :09/24/040/00153/AM20/	Lic.No/Date:0910067703 27.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Metronidazole Injection USP 500mg (5mg/ml), 100ml Bag	1 Number	1	Metronidazole USP	525 mg / 100 ml bag
		2	Injection Port	Relevant Net +1% with accountability
		3	Twist off port stoppers	

RA may take appropriate action as per the decision of Norms Committee

138	**Case No.:87/6/82-ALC4/2019**	Party Name:BRAWN LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00313/AM20/	RLA File :05/23/040/00121/AM20/	Lic.No/Date:0510411076 27.06.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 3/82-ALC4/2019 , dated 05.07.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
CIPROFLOXACIN TABLETS 500MG (OFF WHITE, ELONGATED, BICONVEX, FLIM COATED TABLET, SCORED ON ONE SIDE)	One 500 mg tablet	1.	CIPROFLOXACIN HYDROCHLORIDE USP (FAINTLY YELLOWISH TO LIGHT YELLOW CRYSTALS)	555.0 mg / 500 mg Tablets

RA concerned may take further necessary action as per above decision of NC.

139	**Case No.:88/6/82-ALC4/2019**	Party Name:DIVIS LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00314/AM20/	RLA File :09/24/040/00151/AM20/	Lic.No/Date:0910067706 27.06.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

140	**Case No.:89/6/82-ALC4/2019**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00315/AM20/	RLA File :09/24/040/00157/AM20/	Lic.No/Date:0910067709 27.06.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

141	**Case No.:90/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00316/AM20/	RLA File :03/95/040/00268/AM20/	Lic.No/Date:0310829959 27.06.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

142	**Case No.:91/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00317/AM20/	RLA File :03/95/040/00190/AM20/	Lic.No/Date:0310829960 27.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

143	**Case No.:92/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00318/AM20/	RLA File :03/95/040/00267/AM20/	Lic.No/Date:0310829964 27.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

144	**Case No.:93/6/82-ALC4/2019**	Party Name:CONCORD BIOTECH LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00319/AM20/	RLA File :08/24/040/00101/AM20/	Lic.No/Date:0810145581 27.06.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Ahmedabad.			

145	**Case No.:95/6/82-ALC4/2019**	Party Name:RECKITT BENCKISER HEALTHCARE INDIA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00321/AM20/	RLA File :05/24/040/00196/AM20/	Lic.No/Date:0510411088 27.06.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Cepacol Extra Strength Lozenges Cherry	1 Number tablet (Lozenges)	1	ISOMALT ST-M	1822.00 mg / tablet
		2	Lycasin 80/55 (Maltitol)	456.00 mg / tablet
		3	D&C red no. 33	0.055 mg / tablet
		4	FD&C Red no. 40	0.073 mg / tablet
		5	Benzocaine USP	15.30 mg / tablet
		6	Wild Cherry Flavour TAK 040489	12.71 mg / tablet
		7	Cherry Bark FL NAT TAK 054757	4.90 mg /tablet
		8	Intensate Cool Flavour TAK052848	4.70 mg / tablet

RA concerned may take further necessary action as per above decision of NC.

146	**Case No.:96/6/82-ALC4/2019**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00322/AM20/	RLA File :09/24/040/00158/AM20/	Lic.No/Date:0910067713 27.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Milrinone Lactate Injection 1mg/ml, 50ml Vial	1 Number	1	Milrinone	52.5 mg / 50 ml vial
		2	Glass Vials	Relevant as per packing Policy
		3	Rubber Stoppers	
		4	Flip off Seals	

RA may take appropriate action as per the decision of Norms Committee

147	**Case No.:97/6/82-ALC4/2019**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00323/AM20/	RLA File :07/24/040/00063/AM20/	Lic.No/Date:0710115110 27.06.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
MAGNESIUM PIDOLATE(Eur.Ph)	1 kg	1.	L-PYROGLUTAMIC ACID	0.90 kg
CALCIUM PIDOLATE	1 kg	1.	L-PYROGLUTAMIC ACID	0.82 kg

RA concerned may take further necessary action as per above decision of NC.

148	**Case No.:94/6/82-ALC4/2019**	Party Name:T& T PHARMA CARE	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00320/AM20/	RLA File :03/95/040/00300/AM20/	Lic.No/Date:0310829994 28.06.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
LUMICAR (Pilocarpine HCL eye drop BP 4%) (Each 10 ml bottle contains Pilocarpine HCL BP 0.4 gm)	36000Number	1	PILOCARPINE HCL BP	14.70 kg

RA may take appropriate action as per the decision of Norms Committee

149	**Case No.:98/6/82-ALC4/2019**	Party Name:RECKITT BENCKISER HEALTHCARE INDIA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00324/AM20/	RLA File :05/24/040/00199/AM20/	Lic.No/Date:0510411091 28.06.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Cepacol Extra Strength Lozenges-Honey Lemon	1 Number	1	ISOMALT ST-M	2313.35 mg / tablet
		2	D&C YELLOW NO. 10	0.44 mg / tablet
		3	FD&C YELLOW NO. 6	0.007 mg/ tablet
		4	BENZOCAINE USP	15.30 mg / tablet
		5	HONEY & LEMON FLAVOUR TAK 042202	6.444 mg / tablet
		6	INTENSATE COOL FLAV TAK 052848	4.70 mg / tablet
		7	MOUTHFEEL ENHANCER TAK 053628	2.30 mg / tablet

RA concerned may take further necessary action as per above decision of NC.

150	**Case No.:99/6/82-ALC4/2019**	Party Name:RECKITT BENCKISER HEALTHCARE INDIA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00325/AM20/	RLA File :05/24/040/00202/AM20/	Lic.No/Date:0510411103 01.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Cepacol Extra Strength Lozenges-Sore throat & Cough Mixed Berry	1 Number	1	ISOMALT ST-M	2320.080 mg / tablet
		2	FD&C Red No. 40	0.259 mg / tablet
		3	Spectracol Dual FD&C Blue No. 1	0.001 mg / tablet
		4	Benzocaine USP	8.1864 mg / tablet
		5	Berry Flavour TAK 041362	8.152 mg / tablet
		6	Intensate Masking TAK 041943	4.485 mg / tablet

RA concerned may take further necessary action as per above decision of NC.

151	**Case No.:100/6/82-ALC4/2019**	Party Name:STYRAX PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00326/AM20/	RLA File :26/24/040/00004/AM20/	Lic.No/Date:2610012878 01.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
5-(4-AMINO-2-OXO-PYRIMIDINYL)-OXATHIOLANE-2-CARBOXYLIC ACID-ISOPROPYL-METHYL-CYCLOHEXYL ESTER OR CHE	1 kg	1	GLYOXALIC ACID 50%	0.746 kg
		2	2,5-DIHYDROXY-1,4-DIATHINE	0.327 kg
		3	DI METHYL FORMAMIDE (DMF)	0.260 kg
		4	CYTOSINE	0.434 kg
		5	HEXA METHYL DISILAZANE (HMDS)	0.708 kg
		6	METHYLENE DI CHLORIDE (MDC)	2.630 kg
		7	L-MENTHOL (FRESH / RECOVERY)	0.751 kg
		8	TRI ETHYL AMINE (TEA)	0.034 kg
		9	TRIPHOSGENE	0.40 kg

RA may take appropriate action as per the decision of Norms Committee

152	**Case No.:101/6/82-ALC4/2019**	Party Name:STYRAX LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00327/AM20/	RLA File :26/24/040/00005/AM20/	Lic.No/Date:2610012879 01.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
5-(4-AMINO-2-OXO-PYRIMIDINYL)-OXATHIOLANE-2-CARBOXYLIC ACID-ISOPROPYL-METHYL-CYCLOHEXYL ESTER OR CHE	1 kg	1	GLYOXALIC ACID 50%	0.746 kg
		2	2,5-DIHYDROXY-1,4-DIATHINE	0.327 kg
		3	DI METHYL FORMAMIDE (DMF)	0.260 kg
		4	CYTOSINE	0.434 kg
		5	HEXA METHYL DISILAZANE (HMDS)	0.708 kg
		6	METHYLENE DI CHLORIDE (MDC)	2.630 kg
		7	L-MENTHOL (FRESH / RECOVERY)	0.751 kg
		8	TRI ETHYL AMINE (TEA)	0.034 kg
		9	TRIPHOSGENE	0.40 kg

RA may take appropriate action as per the decision of Norms Committee

153	**Case No.:102/6/82-ALC4/2019**	Party Name:RAJASTHAN ANTIBIOTICS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00328/AM20/	RLA File :05/24/040/00200/AM20/	Lic.No/Date:0510411121 02.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Ampicillin Sodium Sterile+ Sulbactam Sodium Sterile (Ratio:2x1, 2400+1200 KG)	3600 kg	1	Ampicillin Trihydrate	2880 kg
		2	Sulbactam Sodium Sterile	1200 kg

RA may take appropriate action as per the decision of Norms Committee

154	**Case No.:103/6/82-ALC4/2019**	Party Name:SMILAX LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00329/AM20/	RLA File :09/24/040/00146/AM20/	Lic.No/Date:0910067735 02.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

155

Case No.:104/6/82-ALC4/2019	Party Name:CHROMO LABORATORIES INDIA PVT LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
HQ File :01/82/050/00330/AM20/	RLA File :09/24/040/00143/AM20/	Lic.No/Date:0910067737 02.07.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Candesartan Cilexetil 100% BG condition imposed.	1 kg	1	3-Nitrophthalic Acid	1.352 kg
		2	4-Bromomethyl-2-cyanobiphenyl	1.66 kg
		3	Hydrazine Hydrate	1.65 kg
		4	1-Chloro Ethyl Cyclohexyl Carbonate	0.672 kg
		5	Tetra Ethyl Ortho Carbonate	1.19 kg
		6	Trityl Chloride	1.216 kg
		7	Potassium Carbonate	3.096 kg
		8	Sodium Azide	1.68 kg
		9	Acetone	11.00 kg
		10	Dimethyl Formamide	3.32 kg
		11	Methanol	8.55 kg
		12	Methylene Chloride	21.75 kg

RA concerned may take further necessary action as per above decision of NC.

156

Case No.:105/6/82-ALC4/2019	Party Name:HETERO LABS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
HQ File :01/82/050/00331/AM20/	RLA File :09/24/040/00160/AM20/	Lic.No/Date:0910067738 02.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
2-CHLORO-N-(2-CHLORO-4-METHYL-3-PYRIDINYL)-3-PYRIDINE CARBOXAMIDE	1 kg	1	2-CHOLORO NICLOTINIC ACID	0.71 kg
		2	THIONYL CHLORIDE	0.90 kg
		3	N N DI METHYL FORMAMIDE	0.040 kg
		4	3-AMINO 2-CHLORO-4-METHYL PYRIDINE	0.540 kg
		5	TETRA BUTYL AMMONIUM BROMIDE	0.197 kg
		6	TOLUENE	3.65 kg
		7	METHANOL	0.087 kg

RA may take appropriate action as per the decision of Norms Committee

157

Case No.:106/6/82-ALC4/2019	Party Name:VIVIMED LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
HQ File :01/82/050/00332/AM20/	RLA File :09/24/040/00155/AM20/	Lic.No/Date:0910067740 03.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product:

Losartan Potassium Tablets USP (Losartan) 25 Mg, 50 Mg, 100 Mg

Sl. No.	Import items	Norms Recommended for one Tablet		
		25 Mg Tablet	50 Mg Tablet	100 Mg Tablet
1	Losartan Potassium (or) Losartan Potasium USP	25.5 mg	51 mg	102 mg
2	Mannitol (Pearlitol 160C)	101.9 mg	203.8 mg	407.6 mg
3	Microcrystalline Cellulose (Avicel PH 102)	40.5 mg	81.0 mg	162 mg
4	Croscarmellose Sodium (Ac Di Sol)	7.19 mg	14.38 mg	28.76 mg
5	Povidone(PLASDONE K-29/32)	3.61 mg	7.22 mg	14.44 mg
6	Magnesium Stearate (Mallinckrodt 2257)	1.8 mg	3.6 mg	7.2 mg
7	Opadry White (03H28419)	3.6 mg	7.2 mg	14.4 mg

RA may take appropriate action as per the decision of Norms Committee.

158	**Case No.:107/6/82-ALC4/2019**	Party Name:VIVIMED LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00333/AM20/	RLA File :09/24/040/00156/AM20/	Lic.No/Date:0910067741 03.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

159	**Case No.:108/6/82-ALC4/2019**	Party Name:FRESENIUS KABI ONCOLOGY LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00334/AM20/	RLA File :05/23/040/00129/AM20/	Lic.No/Date:0510411135 03.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from CLA, New Delhi.			

160	**Case No.:109/6/82-ALC4/2019**	Party Name:BRAWN LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00335/AM20/	RLA File :05/23/040/00131/AM20/	Lic.No/Date:0510411137 03.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
ACICLOVIR TABLETS BP 200 MG WHITE ROUND FLAT SCORED ON ONE SIDE UNCOATED TABLETS	1 Number	1	ACICLOVIR BP WHITE OR ALMOST WHITE CRYSTALLINE POWDER	204.0 mg / 200 mg tablet
ACICLOVIR TABLETS BP 400 MG WHITE ROUND FLAT SCORED ON ONE SIDE UNCOATED TABLETS	1 Number	1	ACICLOVIR BP WHITE OR ALMOST WHITE CRYSTALLINE POWDER	408.0 mg / 400 mg tablet

RA may take appropriate action as per the decision of Norms Committee

161	**Case No.:110/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00336/AM20/	RLA File :03/95/040/00266/AM20/	Lic.No/Date:0310830037 03.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

162	**Case No.:111/6/82-ALC4/2019**	Party Name:BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00337/AM20/	RLA File :03/94/040/00263/AM20/	Lic.No/Date:0310830039 03.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Leflunomide 6.66% DCG	500 kg	1	Leflunomide	33.633 kg

RA may take appropriate action as per the decision of Norms Committee

163	**Case No.:112/6/82-ALC4/2019**	Party Name:MAHARSHI PHARMA CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00338/AM20/	RLA File :08/24/040/00112/AM20/	Lic.No/Date:0810145626 03.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

164	**Case No.:113/6/82-ALC4/2019**	Party Name:BODAL CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00339/AM20/	RLA File :08/24/040/00111/AM20/	Lic.No/Date:0810145627 03.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
SULFO PARA BASE ESTER (SULFO VINYL SULPHONE ESTER)	1 kg	1	ANILINE OIL	0.500 kg
		2	ACETIC ACID(GLACIAL)	0.400 kg
		3	SULPHUR	0.927 kg
		4	CAUSTIC SODA FLAKES / LYE	0.832 kg
		5	ETHYLENE OXIDE	0.241 kg
		6	SODA ASH	0.170 kg
		7	POTASSIUM CHLORIDE	0.588 kg

RA may take appropriate action as per the decision of Norms Committee

165	**Case No.:114/6/82-ALC4/2019**	Party Name:TITAN LABORATORIES PVT. LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00340/AM20/	RLA File :03/95/040/00318/AM20/	Lic.No/Date:0310830043 03.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

166	**Case No.:115/6/82-ALC4/2019**	Party Name:ELPPE CHEMICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00341/AM20/	RLA File :03/94/040/00266/AM20/	Lic.No/Date:0310830047 03.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

167	**Case No.:117/6/82-ALC4/2019**	Party Name:SYNTHO CHIRALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00343/AM20/	RLA File :09/24/040/00172/AM20/	Lic.No/Date:0910067749 03.07.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.

168	**Case No.:118/6/82-ALC4/2019**	Party Name:DEEPAK NITRITE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00344/AM20/	RLA File :34/24/040/00056/AM20/	Lic.No/Date:3410045252 03.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 3/82-ALC4/2019 , dated 05.07.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
2- ETHYL HEXYL NITRATE	1 kg	1	2-ETHYL HEXANOL	0.748 kg
		2	NITRIC ACID	Not allowed
		3	SULPHURIC ACID	Not allowed
		4	SODA ASH	Not allowed

RA concerned may take further necessary action as per above decision of NC.

169	**Case No.:116/6/82-ALC4/2019**	Party Name:LUPIN LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00342/AM20/	RLA File :03/95/040/00301/AM20/	Lic.No/Date:0310830087 04.07.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

170	**Case No.:119/6/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00345/AM20/	RLA File :03/94/040/00261/AM20/	Lic.No/Date:0310830091 04.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	Clobetasol Propionate Cream USP 0.05% (Pack Size 15gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.750 Kgs)	100000 Packs	1	CLOBETASOL PROPIONATE USP (MICRONIZED)	17.07 kg
2	Clobetasol Propionate Cream USP 0.05% (Pack size 30gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.300 Kgs)	20000 Packs			
3	Clobetasol Propionate Cream USP 0.05% (Pack size 45 gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.450 Kgs)	20000 Packs			
4	Clobetasol Propionate Cream USP 0.05% (Pack size 60gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.600 Kgs)	20000 Packs			
5	Clobetasol Propionate Ointment USP 0.05% (Pack size 15gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.150 Kgs)	20000 Packs			
6	Clobetasol Propionate Ointment USP 0.05% (Pack size 30gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.750 Kgs)	50000 Packs			
7	Clobetasol Propionate Ointment USP 0.05% (Pack size 45gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.900 Kgs)	40000 Packs			
8	Clobetasol Propionate Ointment USP 0.05% (Pack size 60gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.600 Kgs)	20000 Packs			
9	Clobetasol Propionate Spray 0.05% (Pack size 59ml) (Net Weight of Clobetasol Propionate USP (Micronized) 1.180 Kgs)	40000 Packs			
10	Clobetasol Propionate Spray 0.05% (Pack size 125ml) (Net Weight of Clobetasol Propionate USP (Micronized) 1.250 Kgs)	20000 Packs			
11	Clobetasol Prop. Top Sol USP, 0.05% 25ml (Net Weight of Clobetasol Propionate USP (Micronized) 0.625 Kgs)	50000 Packs			

12	Clobetasol Prop. Top Sol USP, 0.05% 50ml (Net Weight of Clobetasol Propionate USP (Micronized) 0.500 Kgs)	20000 Packs			
13	Clobetasol Pro Shampoo, 0.05 % 118ml (Net Weight of Clobetasol Propionate USP (Micronized) 1.180 Kgs)	20000 Packs			
14	Clobetasol Propionate Foam 0.05% 50gm (Net. wt. of Net. wt. of Clobetasol Propionate USP (Micronized) is 2.500 Kgs.)	100000 Packs			
15	Clobetasol Propionate Foam 0.05% 100gm (Net. wt. of Clobetasol Propionate USP (Micronized) is 5.000 Kgs.)	100000 Packs			

RA may take appropriate action as per the decision of Norms Committee

171	**Case No.:120/6/82-ALC4/2019**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00346/AM20/	RLA File :03/95/040/00322/AM20/	Lic.No/Date:0310830094 04.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

172	**Case No.:121/6/82-ALC4/2019**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00347/AM20/	RLA File :03/95/040/00331/AM20/	Lic.No/Date:0310830121 05.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

173	**Case No.:122/6/82-ALC4/2019**	Party Name:PROLIFE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00348/AM20/	RLA File :03/95/040/00329/AM20/	Lic.No/Date:0310830123 05.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

174	**Case No.:123/6/82-ALC4/2019**	Party Name:OLIVE HEALTHCARE	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00349/AM20/	RLA File :03/95/040/00317/AM20/	Lic.No/Date:0310830125 05.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
TEMAZEPAM TEVA 10 MG CAPSULES	6000000 Number	1	TEMAZEPAM Ph Eur	142.80 kg
TEMAZEPAM TEVA 20 MG CAPSULES	3999990 Number			

RA may take appropriate action as per the decision of Norms Committee.

175	**Case No.:124/6/82-ALC4/2019**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00350/AM20/	RLA File :05/24/040/00177/AM20/	Lic.No/Date:0510411161 05.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Inj. Adrenaline 1mg/ml,1ml Amp (Adrenaline acid tartrate BP 1.8mg eq. Adrenaline base 1mg /ml, 1ml Amp)	405000 Number	1	Adrenaline Acid Bitartrate	0.802 kg

RA may take appropriate action as per the decision of Norms Committee.

176	**Case No.:125/6/82-ALC4/2019**	Party Name:SOHAN HEALTHCARE PVT. LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00351/AM20/	RLA File :31/83/040/00052/AM20/	Lic.No/Date:3110067465 05.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
METFORMIN HYDROCHLORIDE BP/EP WHITE CRYSTLLINE POWDER	1 kg	1	DICYANDIAMIDE (DCDA) WHITE POWDER	0.567 kg

RA concerned may take further necessary action as per above decision of NC.

177	**Case No.:126/6/82-ALC4/2019**	Party Name:SENTISS PHARMA PVT.LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00352/AM20/	RLA File :05/24/040/00216/AM20/	Lic.No/Date:0510411169 05.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Dancil Eye & Ear Drops .3% 5ml	1 Pack	1	Ofloxacin	0.0153 gm / 5 ml pack

RA may take appropriate action as per the decision of Norms Committee.

178	**Case No.:127/6/82-ALC4/2019**	Party Name:APNAR PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00353/AM20/	RLA File :34/24/040/00098/AM20/	Lic.No/Date:3410045258 05.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

179	**Case No.:128/6/82-ALC4/2019**	Party Name:PANACEA BIOTEC LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00354/AM20/	RLA File :05/24/040/00217/AM20/	Lic.No/Date:0510411176 08.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

180	**Case No.:129/6/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00355/AM20/	RLA File :03/94/040/00277/AM20/	Lic.No/Date:0310830153 08.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Lidocaine Ointment USP 5% (Pack Size 35.44gms)	125000 Number	1	LIDOCAINE USP	225.93 kg
Lidocaine Ointment USP 5% (Pack Size 50gms)	135000 Number	1	LIDOCAINE USP	344.25 kg

RA may take appropriate action as per the decision of Norms Committee

181	**Case No.:130/6/82-ALC4/2019**	Party Name:ACME GENERICS LLP	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00356/AM20/	RLA File :22/24/040/00026/AM20/	Lic.No/Date:2210016194 08.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

182	**Case No.:142/6/82-ALC4/2019**	Party Name:LANTECH PHARMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00368/AM20/	RLA File :09/24/040/00177/AM20/	Lic.No/Date:0910067759 09.07.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
N,N-CARBONYL DIIMIDAZOLE	1 kg	1	Imidazole	1.31 kg
		2	Triphosgene	1.20 kg
		3	Tributylamine	1.78 kg
		4	Toluene	2.20 kg

RA concerned may take further necessary action as per above decision of NC.

183	**Case No.:143/6/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00369/AM20/	RLA File :03/94/040/00279/AM20/	Lic.No/Date:0310830168 09.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
AZELAIC ACID GEL 15% (Pack Size 50 Grams)	250000 Packs	1	Azelaic Acid	1912.50 kg

RA may take appropriate action as per the decision of Norms Committee

184	**Case No.:144/6/82-ALC4/2019**	Party Name:LACTOSE (INDIA) LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00370/AM20/	RLA File :03/95/040/00296/AM20/	Lic.No/Date:0310830184 09.07.2019	

Decision: The Committee considered the case as per agenda in the presence of technical experts and it was decided to call for following information:

(i) Certificate of Analysis (CoA) of import item from foreign supplier.
(ii) Certificate of Analysis (CoA) of export item from the party.

185	**Case No.:145/6/82-ALC4/2019**	Party Name:MAHARSHI PHARMA CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00371/AM20/	RLA File :08/24/040/00114/AM20/	Lic.No/Date:0810145666 09.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

186	**Case No.:146/6/82-ALC4/2019**	Party Name:MAHARSHI PHARMA CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00372/AM20/	RLA File :08/24/040/00115/AM20/	Lic.No/Date:0810145667 09.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

187	**Case No.:149/6/82-ALC4/2019**	Party Name:RAVOOS LABORATORIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00375/AM20/	RLA File :09/24/040/00183/AM20/	Lic.No/Date:0910067761 09.07.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Azithromycin Dihydrate Taste Masked Granules 7.5% w/w / Azithromycin Taste Masked Granules 7.5% w/w.	20000 kg	1	Azithromycin Dihydrate	1604 kg

RA concerned may take further necessary action as per above decision of NC.

188	**Case No.:150/6/82-ALC4/2019**	Party Name:MAHARSHI PHARMA CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00376/AM20/	RLA File :08/24/040/00116/AM20/	Lic.No/Date:0810145668 09.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

189	**Case No.:151/6/82-ALC4/2019**	Party Name:MAHARSHI PHARMA CHEM PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00377/AM20/	RLA File :08/24/040/00117/AM20/	Lic.No/Date:0810145669 09.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

190	**Case No.:147/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00373/AM20/	RLA File :03/94/040/00281/AM20/	Lic.No/Date:0310830195 10.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

191	**Case No.:148/6/82-ALC4/2019**	Party Name:THINQ PHARMA CRO LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00374/AM20/	RLA File :03/95/040/00338/AM20/	Lic.No/Date:0310830207 10.07.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

192	**Case No.:152/6/82-ALC4/2019**	Party Name:JUBILANT GENERICS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00378/AM20/	RLA File :05/23/040/00152/AM20/	Lic.No/Date:0510411213 10.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import Item	Qty.
Amantadine HCl Tablet 100mg	1 tablet	1	Amantadine Hydrochloride	102 mg/ 100 mg tablet

RA concerned may take further necessary action as per above decision of NC.

193	**Case No.:153/6/82-ALC4/2019**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00379/AM20/	RLA File :09/24/040/00195/AM20/	Lic.No/Date:0910067774 11.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Chlorothiazide Sodium for Injection, USP 500mg/vial, 20ml Vial USP	1 Number	1	Chlorothiazide USP	525 mg / 20 ml vial
		2	Glass Vials	Relevant as per Packing Policy
		3	Rubber Stoppers	
		4	Flip off Seals	

RA may take appropriate action as per the decision of Norms Committee.

194	**Case No.:154/6/82-ALC4/2019**	Party Name:INDO AMINES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00380/AM20/	RLA File :03/94/040/00122/AM20/	Lic.No/Date:0310830244 12.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

195	**Case No.:155/6/82-ALC4/2019**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00381/AM20/	RLA File :03/95/040/00335/AM20/	Lic.No/Date:0310830246 12.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

196	**Case No.:156/6/82-ALC4/2019**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00382/AM20/	RLA File :03/95/040/00356/AM20/	Lic.No/Date:0310830257 12.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

197	**Case No.:157/6/82-ALC4/2019**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00383/AM20/	RLA File :09/24/040/00187/AM20/	Lic.No/Date:0910067778 12.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

198

	Case No.:158/6/82-ALC4/2019	Party Name:SYNNAT PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00384/AM20/	RLA File :02/24/040/00056/AM20/	Lic.No/Date:0210209307 12.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Noscapine BP USP Ph.Eur JP CP / Noscapine Hydrochloride BP Ph.Eur	1 kg	1	Noscapine Crude Content 95%	1.10 kg

RA concerned may take further necessary action as per above decision of NC.

199	**Case No.:159/6/82-ALC4/2019**	Party Name:SOMU ORGANO CHEM PVT.LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00385/AM20/	RLA File :07/24/040/00088/AM20/	Lic.No/Date:0710115163 12.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018, dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
1,3-CYCLOHEXANEDIONE	1 kg	1	RESORCINOL	1.196 kg

RA concerned may take further necessary action as per above decision of NC.

200	**Case No.:162/6/82-ALC4/2019**	Party Name:ANG LIFESCIENCES INDIA LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00388/AM20/	RLA File :30/24/040/00064/AM20/	Lic.No/Date:3010104756 12.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

201	**Case No.:160/6/82-ALC4/2019**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00386/AM20/	RLA File :03/95/040/00363/AM20/	Lic.No/Date:0310830298 15.07.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

202	**Case No.:161/6/82-ALC4/2019**	Party Name:INDO AMINES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00387/AM20/	RLA File :03/94/040/00292/AM20/	Lic.No/Date:0310830304 15.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
TETRA BUTYL UREA / IAL TBU / 1,1,3,3-TETRABUTYLUREA	1 kg	1	DI N BUTYL AMINE	1.00 kg
		2	TRIPHOSGENE	0.319 kg

RA may take appropriate action as per the decision of Norms Committee

203	**Case No.:163/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00389/AM20/	RLA File :03/95/040/00294/AM20/	Lic.No/Date:0310830351 16.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

204	**Case No.:164/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00390/AM20/	RLA File :03/95/040/00293/AM20/	Lic.No/Date:0310830352 16.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

205	**Case No.:165/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00391/AM20/	RLA File :03/95/040/01002/AM19/	Lic.No/Date:0310830355 16.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

206	**Case No.:166/6/82-ALC4/2019**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00392/AM20/	RLA File :31/83/040/00061/AM20/	Lic.No/Date:3110067474 16.07.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 12/82-ALC4/2018 dated 12.12..2018, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export Product	Qty.	Sl. No.	Import Items	Qty.
GAMMA BUTYROLACTONE	1 kg	1.	1,4 BUTANEDIOL	1.16 kg
		2.	GBL CATAYLYST	0.001 kg

RA may take appropriate action as per the decision of Norms Committee.

207	**Case No.:167/6/82-ALC4/2019**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00393/AM20/	RLA File :31/83/040/00060/AM20/	Lic.No/Date:3110067475 16.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 3/82-ALC4/2019 , dated 05.07.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
N-METHYL-2-PYRROLIDONE	1 kg	1	METHANOL	0.370 kg
		2	AMMONIA ANHYDROUS	0.160 kg
		3	1,4 BUTANEDIOL	1.044 kg
		4	METHYLAMINE CATALYST	0.00080 kg
		5	GBL CATALYST	0.00075 kg

RA concerned may take further necessary action as per above decision of NC.

208	**Case No.:168/6/82-ALC4/2019**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00394/AM20/	RLA File :31/83/040/00062/AM20/	Lic.No/Date:3110067476 16.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 3/82-ALC4/2019 , dated 05.07.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
N-ETHYL-2-PYRROLIDONE	1 kg	1	GAMMA BUTYROLACTONE	0.72 kg
		2	MONOETHYLAMINE 70% SOLUTION	0.533 kg

RA concerned may take further necessary action as per above decision of NC.

209	**Case No.:204/6/82-ALC4/2019**	Party Name:ZENITH DYEINTERMEDIATES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00430/AM20/	RLA File :03/95/040/00306/AM20/	Lic.No/Date:0310830334 16.07.2019	

Decision: The Committee considered the cases as per agenda and in the light of earlier decision taken in meeting no. 5/82-ALC4/2019 dated 02.08.2019, it was decided to ratify norms under Para 4.7 of HBP v1 as per details given below or as applied by the firm, whichever is less:

Export product	Qty.	Sl. No.	Import items	Qty.
NAS-5 (2-DIAZO-1-NAPTHOL-5-SULFONIC ACID, SODIUM SALT)	1 kg	1	TOBIAS ACID (PURITY MIN. 97%)	1.618 kg

RA may take appropriate action as per the decision of Norms Committee.

210	**Case No.:169/6/82-ALC4/2019**	Party Name:PRACHEM LABORATORIES	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00395/AM20/	RLA File :08/24/040/00123/AM20/	Lic.No/Date:0810145731 17.07.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Ahmedabad.

211	**Case No.:170/6/82-ALC4/2019**	Party Name:RUBICON RESEARCH PVT. LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00396/AM20/	RLA File :03/95/040/00251/AM20/	Lic.No/Date:0310830404 18.07.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

212	**Case No.:171/6/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00397/AM20/	RLA File :03/94/040/00311/AM20/	Lic.No/Date:0310830410 18.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 13/82-ALC4/2018, dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	Mupirocin Ointment USP 2% (Pack Size 22gms)	1 pack	1	Mupirocin USP	0.4488 gm/22 gm pack
2	Supiroban 15gm Ointment ZA (Pack Size 15gms)	1 pack	1	Mupirocin USP	0.306 gm/15 gm pack
3	Supiroban 14gm zulu Ointment (Pack Size 14gms)	1 pack	1	Mupirocin USP	0.2856 mg/14 gm pack
4	Supiroban 50gm Ointment (Pack Size 50gms)	1 pack	1	Mupirocin USP	0.51 gm/50 gm pack

RA may take appropriate action as per the decision of Norms Committee.

213	**Case No.:203/6/82-ALC4/2019**	Party Name:SONGWON SPECIALTY CHEMICALS INDIA PVT. LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00429/AM20/	RLA File :34/24/040/00069/AM20/	Lic.No/Date:3410045298 18.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

214	**Case No.:206/6/82-ALC4/2019**	Party Name:WINDLAS HEALTH CARE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00432/AM20/	RLA File :61/24/040/00005/AM20/	Lic.No/Date:6110001607 18.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Acyclovir Capsules 200 mg Anti Viral Drug	1 Number	1	Acyclovir	204 mg / 200 mg Tablet

RA may take appropriate action as per the decision of Norms Committee

215	**Case No.:199/6/82-ALC4/2019**	Party Name:CIRON DRUGS & PHARMACEUTICALS P. LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00425/AM20/	RLA File :03/94/040/00312/AM20/	Lic.No/Date:0310830435 19.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

216	**Case No.:205/6/82-ALC4/2019**	Party Name:BODAL CHEMICALS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00431/AM20/	RLA File :08/24/040/00128/AM20/	Lic.No/Date:0810145761 22.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
SULFO PARA BASE ESTER (SULFO VINYL SULPHONE ESTER)	1 kg	1	ANILINE OIL	0.500 kg
		2	ACETIC ACID(GLACIAL)	0.400 kg
		3	SULPHUR	0.927 kg
		4	CAUSTIC SODA FLAKES / LYE	0.832 kg
		5	ETHYLENE OXIDE	0.241 kg
		6	SODA ASH	0.170 kg
		7	POTASSIUM CHLORIDE	0.588 kg

RA may take appropriate action as per the decision of Norms Committee

217	**Case No.:209/6/82-ALC4/2019**	Party Name:WINDLAS HEALTH CARE PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00435/AM20/	RLA File :61/24/040/00004/AM20/	Lic.No/Date:6110001608 22.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Amiloride HCI Tablet 5 mg antikaliuretic diuretic agent	1 Number	1	Amiloride Hydrochloride	5.10 mg / 5 mg Tablet

RA may take appropriate action as per the decision of Norms Committee

218	**Case No.:207/6/82-ALC4/2019**	Party Name:PRACHI PHARMACEUTICALS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00433/AM20/	RLA File :03/95/040/00406/AM20/	Lic.No/Date:0310830498 23.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 3/82-ALC4/2019 , dated 05.07.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
THIAMINE HYDRO CHLORIDE	1 kg	1	THIAMINE MONONITRATE	1.02 kg

RA concerned may take further necessary action as per above decision of NC.

219	**Case No.:208/6/82-ALC4/2019**	Party Name:VISION DRUGS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00434/AM20/	RLA File :09/24/040/00210/AM20/	Lic.No/Date:0910067812 23.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

220	**Case No.:210/6/82-ALC4/2019**	Party Name:HETERO LABS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00436/AM20/	RLA File :09/24/040/00212/AM20/	Lic.No/Date:0910067817 23.07.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.

221	**Case No.:244/6/82-ALC4/2019**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00470/AM20/	RLA File :09/24/040/00193/AM20/	Lic.No/Date:0910067814 23.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

222	**Case No.:211/6/82-ALC4/2019**	Party Name:ANWITA DRUGS & CHEMICALS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00437/AM20/	RLA File :09/24/040/00214/AM20/	Lic.No/Date:0910067818 24.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

223	**Case No.:212/6/82-ALC4/2019**	Party Name:HETERO LABS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00438/AM20/	RLA File :09/24/040/00211/AM20/	Lic.No/Date:0910067819 24.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

224

	Case No.:213/6/82-ALC4/2019	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00439/AM20/	RLA File :03/94/040/00323/AM20/	Lic.No/Date:0310830525 24.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
OLMESARTAN MEDOXOMIL	1 kg	1	4-(1-HYDROXY-1-METHYL ETHYL)-2-PROPYL-1H-IMIDAZOLE 5-CARBOXYLIC ACID ETHYL ESTER	0.70 kg
		2	5-(4-BROMOMETHYL BIPHENYL-2-YL)-1-TRITYL-1H-TETRAZOLE 5-(4-BROMOMETHYL) (1,-BROMOMETHYLIPHENYL)-2YL TRIPHENYL-1-H TETRAZOLE	1.35 kg
		3	4-CHLOROMETHYL-5-METHYL 1,3-DIOXOLEN-2-ONE	0.4654 kg
		4	METHYLENE CHLORIDE (MDC)	3.50 kg
		5	TOLUENE	2.50 kg
		6	DIMETHYL FORMAMIDE (DMF)	1.50 kg

RA may take appropriate action as per the decision of Norms Committee

225	**Case No.:214/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00440/AM20/	RLA File :03/94/040/00324/AM20/	Lic.No/Date:0310830527 24.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

226	**Case No.:215/6/82-ALC4/2019**	Party Name:DEEPAK NOVOCHEM TECHNOLOGIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00441/AM20/	RLA File :31/83/040/00047/AM20/	Lic.No/Date:3110067483 24.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Pune.			

227	**Case No.:216/6/82-ALC4/2019**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00442/AM20/	RLA File :03/95/040/00413/AM20/	Lic.No/Date:0310830547 24.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

228	**Case No.:217/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00443/AM20/	RLA File :03/95/040/00387/AM20/	Lic.No/Date:0310830566 25.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

229	**Case No.:218/6/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00444/AM20/	RLA File :03/94/040/00335/AM20/	Lic.No/Date:0310830585 25.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Sl. No.	Export product	Qty	Sl. No.	Import items	Qty.
1	Mometasone Furoate Ointment 0.10% (Pack 10gms) (Net Wt. of Mometasone Furoate Micronized 0.180 Kgs.)	18000 Packs	1	Mometasone Furoate Micronized	50.287 kg
2	Mometasone Furoate Ointment 0.10% (Pack 15gms) (Net Wt. of Mometasone Furoate Micronized 0.270 Kgs.)	18000 Packs			
3	Mometasone Furoate Ointment 0.10% /Momate Ointment 0.10% (Pack 20gms) (Net Wt. of Mometasone Furoate Micronized 0.280 Kgs.)	14000 Packs			
4	Mometasone Furoate Ointment 0.10% (Pack 30gms) (Net Wt. of Mometasone Furoate Micronized 3.000 Kgs.)	100000 Packs			
5	Mometasone Furoate Ointment 0.10% (pack 45gms) (Net Wt. of Mometasone Furoate Micronized 4.050 Kgs.)	90000 Packs			
6	Mometasone Furoate Ointment 0.10% (Pack 50gms) (Net Wt. of Mometasone Furoate Micronized 0.405 Kgs.)	8100 Packs			
7	Mometasone Furoate Ointment 0.10% (pack 60gms) (Net Wt. of Mometasone Furoate Micronized 0.570 Kgs.)	9500 Packs			
8	Mometasone Furoate Ointment 0.10% (pack 100gms) (Net Wt. of Mometasone Furoate Micronized 1.900 Kgs.)	19000 Packs			
9	Mometasone Furoate Tropical Solution USP 0.1% (Lotion) (Pack 30ml) (Net Wt. of Mometasone Furoate Micronized 0.360 Kgs.)	12000 Packs			
10	Mometasone Furoate Tropical Solution USP 0.1% (Lotion) (Pack 60ml) (Net Wt. of Mometasone Furoate Micronized 0.396 Kgs.)	6600 Packs			
11	Mometasone Furoate Cream 0.1% (Pack 10gms) (Net Wt. of Mometasone Furoate Micronized 0.210 Kgs.)	21000 Packs			
12	Mometasone Furoate Cream 0.1% (Pack 15gms) (Net Wt. of Mometasone Furoate Micronized 1.050 Kgs.)	70000 Packs			
13	Mometasone Furoate Cream 0.1% (Pack 20gms) (Net Wt. of Mometasone Furoate Micronized 0.100 Kgs.)	5000 Packs			
14	Mometasone Furoate Cream 0.1% /Metactiv Cream 0.10% (Pack 30gms) (Net Wt. of Mometasone Furoate Micronized 2.130 Kgs.)	71000 Packs			

15	Mometasone Furoate Cream 0.1% (Pack 45gms) (Net Wt. of Mometasone Furoate Micronized 1.800 Kgs.)	40000 Packs			
16	Mometasone Furoate Cream 0.1% (Pack 50gms) (Net Wt. of Mometasone Furoate Micronized 3.000 Kgs.)	60000 Packs			
17	Mometasone Furoate Cream 0.1% (Pack 60gms) (Net Wt. of Mometasone Furoate Micronized 0.900 Kgs.)	15000 Packs			
18	Mometasone Furoate Cream 0.1% (Pack 100gms) (Net Wt. of Mometasone Furoate Micronized 28.700 Kgs.)	287000 Packs			

RA may take appropriate action as per the decision of Norms Committee

230

Case No.:219/6/82-ALC4/2019	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
HQ File :01/82/050/00445/AM20/	RLA File :03/94/040/00337/AM20/	Lic.No/Date:0310830586 25.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.
Kit Pack of Norgestimate& Ethinyl Estradiol Tablets USP 0.18mg/0.035mg, 0.215mg/0.035mg and0.25mg/0.035mg (Pack Size 84 Tabs.) (Net Wt. of Norgestimate USP is 0.677 Kgs)	1 Number
Norgestimate& Ethinyl Estradiol Tablets USP 0.25mg/0.035mg (Pack Size84Tabs.)(Net Wt. of Norgestimate USP is 1.575 Kgs,)	1 Number
Norgestimate& Ethinyl Estradiol Tablets USP 0.18mg/0.025mg, 0.215mg/0.025mg, 0.25mg/0.025mg(Ortho Tri Cyclen-Lo) (Pack Size 84 Tabs.) (Net Wt. of Norgestimate USP is 2.086 Kgs.)	1 Number

SI. No.	**Import Items**	**Qty. Allowed for the export of 1 No. Tablet (Quantity in mg)**					
		0.18mg /0.035 mg	0.215mg /0.035 mg	0.25mg /0.035 mg	0.18mg /0.025 mg	0.215mg /0.025 mg	0.25 mg /0.025 mg
1	Norgestimate USP (Micronized)	0.1836	0.2193	0.255	0.1836	0.2193	0.255

RA may take appropriate action as per the decision of Norms Committee

231	**Case No.:220/6/82-ALC4/2019**	Party Name:BHARAT SERUMS & VACCINES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00446/AM20/	RLA File :03/94/040/00313/AM20/	Lic.No/Date:0310830591 25.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

232	**Case No.:221/6/82-ALC4/2019**	Party Name:ALPHAMED FORMULATIONS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00447/AM20/	RLA File :09/24/040/00222/AM20/	Lic.No/Date:0910067834 25.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

233	**Case No.:229/6/82-ALC4/2019**	Party Name:NISARG BIOSCIENCES PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00455/AM20/	RLA File :09/24/040/00221/AM20/	Lic.No/Date:0910067836 25.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

234	**Case No.:223/6/82-ALC4/2019**	Party Name:LITMUS ORGANICS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00449/AM20/	RLA File :03/95/040/00271/AM20/	Lic.No/Date:0310830619 26.07.2019	

Decision: The Committee considered case as per agenda and in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
TRIETHYL PHOSPHONO ACETATE	1 kg	1	TRIETHYL PHOSPHITE	0.823 kg

RA may take appropriate action as per the decision of Norms Committee

235	**Case No.:230/6/82-ALC4/2019**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00456/AM20/	RLA File :09/24/040/00224/AM20/	Lic.No/Date:0910067838 26.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

236	**Case No.:231/6/82-ALC4/2019**	Party Name:SMS LIFESCIENCES INDIA LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00457/AM20/	RLA File :09/24/040/00215/AM20/	Lic.No/Date:0910067841 26.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

237

Case No.:232/6/82-ALC4/2019	Party Name:SARACA LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
HQ File :01/82/050/00458/AM20/	RLA File :09/24/040/00218/AM20/	Lic.No/Date:0910067842 26.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 15/82-ALC4/2018 , dated 22.03.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
GABAPENTIN	1 kg	1	1,1 CYCLOHEXANE DI ACETIC ACID MONOAMIDE (CAM)	1.630 kg

RA concerned may take further necessary action as per above decision of NC.

238	**Case No.:233/6/82-ALC4/2019**	Party Name:BRAWN LABORATORIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00459/AM20/	RLA File :05/23/040/00169/AM20/	Lic.No/Date:0510411373 26.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

239	**Case No.:234/6/82-ALC4/2019**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00460/AM20/	RLA File :09/24/040/00226/AM20/	Lic.No/Date:0910067843 26.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

240	**Case No.:235/6/82-ALC4/2019**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00461/AM20/	RLA File :09/24/040/00225/AM20/	Lic.No/Date:0910067844 26.07.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

241	**Case No.:236/6/82-ALC4/2019**	Party Name:ACME GENERICS LLP	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00462/AM20/	RLA File :22/24/040/00031/AM20/	Lic.No/Date:2210016214 26.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Chandigarh.			

242	**Case No.:237/6/82-ALC4/2019**	Party Name:ACME GENERICS LLP	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00463/AM20/	RLA File :22/24/040/00030/AM20/	Lic.No/Date:2210016215 26.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Chandigarh.			

243	**Case No.:239/6/82-ALC4/2019**	Party Name:ALEOR DERMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00465/AM20/	RLA File :34/24/040/00135/AM20/	Lic.No/Date:3410045317 26.07.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 3/82-ALC4/2018 , dated 05.06.2018, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	Clobetasol Propionate Cream , 0.05% 15 gm (net content of active ingredients = 315.465 gm)	1 Number	Clobetasol Propionate USP (Micronized)	7.65 mg / 15 gm pack
2	Clobetasol Propionate Cream , 0.05% 30 gm (net content of active ingredients = 639.345gm)	1 Number	Clobetasol Propionate USP (Micronized)	15.30 mg / 30 gm pack
3	Clobetasol Propionate Cream , 0.05% 45 gm (net content of active ingredients = 257.333 gm)	1 Number	Clobetasol Propionate USP (Micronized)	22.95 mg / 45 gm/pack
4	Clobetasol Propionate Cream , 0.05% 60 gm (net content of active ingredients =2230.980 gm)	1 Number	Clobetasol Propionate USP (Micronized)	30.60 mg / 60 gm pack

RA concerned may take further necessary action as per above decision of NC.

244	**Case No.:240/6/82-ALC4/2019**	Party Name:ALEOR DERMACEUTICALS LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00466/AM20/	RLA File :34/24/040/00136/AM20/	Lic.No/Date:3410045318 26.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

245	**Case No.:241/6/82-ALC4/2019**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00467/AM20/	RLA File :31/83/040/00068/AM20/	Lic.No/Date:3110067485 26.07.2019	

Decision: The Committee considered case as per agenda and as per earlier decision taken by NC in its 13/82-ALC4/2018 meeting dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-

Export Product	Qty.	Sl. No.	Import items	Qty.
N-METHYL-2-PYRROLIDONE	1 kg	1.	METHANOL	0.37 kg
		2	AMMONIA ANHYDROUS	0.16 kg
		3	GAMMA BUTYROLACTONE	0.90 kg

RA concerned may take further necessary action as per above decision of NC

246	**Case No.:238/6/82-ALC4/2019**	Party Name:WOCKHARDT LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00464/AM20/	RLA File :03/95/040/00426/AM20/	Lic.No/Date:0310830632 29.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

247	**Case No.:242/6/82-ALC4/2019**	Party Name:PANACEA BIOTEC LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00468/AM20/	RLA File :05/24/040/00250/AM20/	Lic.No/Date:0510411383 29.07.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from CLA, New Delhi.

248	**Case No.:243/6/82-ALC4/2019**	Party Name:MAHAVIR SYNTHESIS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00469/AM20/	RLA File :52/24/040/00023/AM20/	Lic.No/Date:5210043127 29.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE..

249	**Case No.:245/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00471/AM20/	RLA File :03/95/040/00327/AM20/	Lic.No/Date:0310830678 30.07.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

250	**Case No.:246/6/82-ALC4/2019**	Party Name:CIPLA LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00472/AM20/	RLA File :03/94/040/00332/AM20/	Lic.No/Date:0310830686 30.07.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Budesonide Inhalation Suspension 0.25mg/2ml Budesonide Respules 0.25mg/2ml (Each 2ml contains Budesonide USP 0.25mg)	1 Number	1	Budesonide USP	0.2625 mg / 0.25 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)
Budesonide Inhalation Suspension 0.50mg/2ml Budesonide Respules 0.50mg/2ml (Each 2ml contains Budesonide USP 0.50mg)	1 Number	1	Budesonide USP	0.525 mg / 0.50 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)
Budesonide Inhalation Suspension 1mg/2ml Budesonide Respules 1mg/2ml (Each 2ml contains Budesonide USP 1mg)	1 Number	1	Budesonide USP	1.05 mg / 1 mg vial
		2	PURELL PE 1840H GRANULES	Relevant, as per Packing Policy on the net weight of empty respules (Net + 5%)

RA concerned may take further necessary action as per above decision of NC.

251	**Case No.:247/6/82-ALC4/2019**	Party Name:SUNSHIELD CHEMICALS LTD.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00473/AM20/	RLA File :03/95/040/00236/AM20/	Lic.No/Date:0310830692 30.07.2019	

Decision: The Committee considered case as per agenda and and in the presence of the technical experts, it was decided to ratify the ad-hoc input output norms as per earlier decision taken by NC in its 4/82-ALC4/2018 meeting dated 19.06.2018 under para 4.7 of HBP as per details below or as applied by firm whichever is lower:

Export Product`	Qty.	Sl. No.	Import Items	Qty.
OCTYLATED DI-PHENYLAMINE (ODPA)	1 kg	1.	DI-PHENYLAMINE	0.405 kg
		2.	DI-ISO BUTYLENE	0.632 kg

RA may take appropriate action as per the decision of Norms Committee

252	**Case No.:249/6/82-ALC4/2019**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00475/AM20/	RLA File :09/24/040/00232/AM20/	Lic.No/Date:0910067851 30.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

253	**Case No.:248/6/82-ALC4/2019**	Party Name:HUBERGROUP INDIA PRIVATE LIMITED.	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00474/AM20/	RLA File :03/94/040/00346/AM20/	Lic.No/Date:0310830713 31.07.2019	Defer Date:

Decision: New Case, deferred for comments of TE.

254	**Case No.:253/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00479/AM20/	RLA File :03/95/040/00381/AM20/	Lic.No/Date:0310830728 01.08.2019	Defer Date:

Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.

255	**Case No.:254/6/82-ALC4/2019**	Party Name:POLYGEL INDUSTRIES PVT.LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00480/AM20/	RLA File :03/95/040/00373/AM20/	Lic.No/Date:0310830745 01.08.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

256	**Case No.:255/6/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Approved**
	HQ File :01/82/050/00481/AM20/	RLA File :03/94/040/00341/AM20/	Lic.No/Date:0310830747 01.08.2019	

Decision: The Committee considered case as per agenda and as per earlier decision taken by NC in its 13/82-ALC4/2018 meeting dated 14.01.2019, it was decided to ratify the ad-hoc input output norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-

Sl. No.	Export product	Qty.	Sl. No.	Import items	Qty.
1	Ursodiol Tablets USP 250mg (Pack Size 100 Tabs.)	1 tablet	1	Ursodiol USP	255 mg / 250 mg tablet
2	Ursodiol Tablets USP 500mg (Pack Size 100 Tabs.)	1 tablet	1	Ursodiol USP	510 mg / 500 mg tablet

RA concerned may take further necessary action as per above decision of NC

257	**Case No.:256/6/82-ALC4/2019**	Party Name:WEXFORD LABORATORIES P LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00482/AM20/	RLA File :07/24/040/00100/AM20/	Lic.No/Date:0710115236 01.08.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Bangalore.			

258	**Case No.:257/6/82-ALC4/2019**	Party Name:EMMENNAR PHARMA PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00483/AM20/	RLA File :09/24/040/00229/AM20/	Lic.No/Date:0910067855 01.08.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

259	**Case No.:258/6/82-ALC4/2019**	Party Name:NISARG BIOSCIENCES PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00484/AM20/	RLA File :09/24/040/00236/AM20/	Lic.No/Date:0910067858 01.08.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

260	**Case No.:264/6/82-ALC4/2019**	Party Name:DEEPAK NOVOCHEM TECHNOLOGIES LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00490/AM20/	RLA File :31/83/040/00051/AM20/	Lic.No/Date:3110067490 02.08.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Pune.			

261	**Case No.:265/6/82-ALC4/2019**	Party Name:GOVIND LABORATORIES PVT. LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00491/AM20/	RLA File :08/24/040/00145/AM20/	Lic.No/Date:0810145905 02.08.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Ahmedabad.			

262	**Case No.:259/6/82-ALC4/2019**	Party Name:VISION DRUGS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00485/AM20/	RLA File :09/24/040/00240/AM20/	Lic.No/Date:0910067863 05.08.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

263	**Case 260/6/82-ALC4/2019**	Party Name:VINDHYA ORGANICS PVT LTD	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00486/AM20/	RLA File :09/24/040/00239/AM20/	Lic.No/Date:0910067864 05.08.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Hyderabad.			

264	**Case No.:261/6/82-ALC4/2019**	Party Name:SUVEN LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00487/AM20/	RLA File :09/24/040/00242/AM20/	Lic.No/Date:0910067865 05.08.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

265	**Case No.:262/6/82-ALC4/2019**	Party Name:SUVEN LIFE SCIENCES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00488/AM20/	RLA File :09/24/040/00244/AM20/	Lic.No/Date:0910067866 05.08.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

266	**Case No.:263/6/82-ALC4/2019**	Party Name:PRASOL CHEMICALS PRIVATE LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00489/AM20/	RLA File :03/95/040/00453/AM20/	Lic.No/Date:0310830795 05.08.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

267	**Case No.:266/6/82-ALC4/2019**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00492/AM20/	RLA File :03/95/040/00326/AM20/	Lic.No/Date:0310830799 05.08.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

268	**Case No.:267/6/82-ALC4/2019**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00493/AM20/	RLA File :03/95/040/00457/AM20/	Lic.No/Date:0310830804 05.08.2019	Defer Date:
	Decision: New Case, deferred for comments of TE.			

269	**Case No.:268/6/82-ALC4/2019**	Party Name:CHEMIESYNTH (VAPI)LTD.,	Meet No/Date:6/82-ALC4/2019 16.08.2019	**Status: Deferred**
	HQ File :01/82/050/00494/AM20/	RLA File :03/94/040/00363/AM20/	Lic.No/Date:0310830809 05.08.2019	Defer Date:
	Decision: New Case. The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization from RLA, Mumbai.			

Meeting ended with thanks to Chair.

*****